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Abstract 
Background 
Rheumatic heart disease (RHD) is an inflammation to the heart that occurs as a complication 
of acute rheumatic fever (ARF), and it may result in permanent damage to the heart valves. 
RHD is caused by repeated events of ARF, resulting into damaged  heart valves. Subsequently 
preventing the heart from pumping blood efficiently by putting excessive strain on the heart. 
Though, RHD is a disease of poverty, it is neglected in developing countries, including South 
Africa. Lack of adequate evidence regarding the cost of RHD has hindered national and 
international actions to prevent RHD related mortality. The objective of this study was to 
estimate the cost of RHD-related health services in a tertiary hospital in the Western Cape, 
South Africa. 
Methods 
A combination of ingredients and step-down costing approaches were used to estimate the 
annual cost of RHD care from health system perspective. All costs were estimated in 2017 
(base year) South African Rand (ZAR) and 3% discount rate to allow depreciation and 
opportunity cost. Data on service utilization rates were collected using a randomly selected 
sample of 100 patient medical records from the Global Rheumatic Heart Disease Registry (the 
REMEDY study), a registry of individuals living with RHD. Patient-level clinical data, including, 
prices and quantities of medications and laboratory tests, were collected from Groote Schuur 
Hospital (GSH). Step-down costing was used to estimate provider time costs and all other 
facility costs such as overheads. REMEDY study and Groote Schuur Hospital (GSH) data were 
aggregated to estimate the total annual costs of RHD care at GSH and the average annual per-
patient cost among REMEDY study participants. One-way univariate sensitivity analysis was 
conducted to deal with uncertainty. 
Results 
The total cost of RHD care at GSH was estimated at $2, 238, 294 (ZAR 27 million) in 2017, with 
surgery costs accounting for 65% of total costs. Per-patient average annual costs, which 
included outpatient care, cardiac medical and intensive care unit (ICU) care, cardiac 
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catheterisation lab procedures, and heart valve surgery, was estimated at $4, 311 (ZAR 52, 
000) per-patient annually. The cost of medications and consumables related to cardiac 
catheterisation and heart valve surgery were the main cost drivers.  
Conclusion 
RHD care consumes a significant level of tertiary hospital resources in South Africa, with 
annual per-patient costs much higher than many other non-communicable and infectious 
diseases. This analysis supports the scaling up of primary and secondary prevention 
programmes at primary health to reduce the future burden on tertiary services. The study 
may also inform resource allocation efforts related to RHD at tertiary and provide cost 
estimates for future studies of intervention cost-effectiveness.  
Keywords 
Unit cost, cost analysis, health systems, provider cost, rheumatic fever, rheumatic heart 
disease, surgery, tertiary care, cardiology 
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1. Background  
Globally, cardiovascular diseases (CVDs) are the foremost contributors to the rising cost 
burden to health systems. A significant literature has established that the epidemiology of 
CVDs differs broadly depending on the resource level of the setting. Resource-poor settings 
are believed to account for over 80% of the world’s mortality related to CVD (Bonow et al., 
2002; Koech & Ngeno, 2014). Resource-poor African countries have a high prevalence of 
CVDs, and these CVDs are the second most common cause of mortality after infectious 
diseases (Koech & Ngeno, 2014). One preventable and treatable form of CVD that is especially 
important in Africa is rheumatic heart disease (RHD).  
Rheumatic heart disease (RHD) is a disease of poverty, mainly occurring in children and young 
adults who have been affected by acute rheumatic fever (ARF), which in itself is a result of 
untreated group A streptococcal sore throat (Watkins et al., 2016). Recurrences of ARF result 
in RHD, where one or more heart valves are damaged by inflammation (Marion et al., 2012). 
Once individual’s heart is affected in such a manner, the heart valves will fail to function 
effectively. RHD is thus a major cause of sequelae such as heart failure, as well as arrhythmias, 
stroke, and infective endocarditis (Watkins, 2015). All these sequelae can affect young school-
going children and economically dynamic and childbearing adults (Araujo, Goulet & Meira, 
2012). The condition leads to gradual disability, loss of quality of life, and eventually 
premature death (Kumar & Tandon, 2013). Performing heart surgery to repair or replace the 
valve (or valves) can minimize these challenges and prolong life, yet its cost is very high 
(Carapetis, Mayosi & Kaplan, 2006; Hewitson & Zilla, 2010).  
Most recent estimates indicate that there are 33 million people who suffer from RHD globally, 
with about 320,000 deaths in 2015 (Naghavi et al. 2015; GBD1, 2015). Predictably, RHD 
prevalence is high in low and middle-income countries (LMICs) (Marijon et al 2012; Cilliers, 
2015), especially in South Asia, Latin America, the Middle East, and Sub-Saharan Africa 
(Mayosi, 2010; Seckeler & Hoke, 2011). Sub-Saharan Africa, which is home for only 10% of 
the world’s population, is thought to account for 50% of children who suffer from RHD (Ntusi 
& Mayosi, 2009). Studies have found that one in five African children with RHD die by the age 
of 15 years, and about 4 in 5 of them die by the age of 25 (Kimbally-Kaky et al. 2002; Oli & 
                                                           
1 The Global Burden of Disease 2015 Study. 
 
3 
  
Asmera, 2004). School based studies in Sub-Saharan Africa indicate that the RHD prevalence 
in children is as high as 30 per thousand, e.g., in Mozambique (Marijon, 2007). Yet there are 
few studies on the epidemiology of RHD in sub-Saharan Africa, including South Africa. One 
recent initiative to assess non-fatal outcomes of individuals with RHD is the REMEDY2 study 
(Engel, 2012).  
However, South Africa’s RHD problem is 25 times higher than the rate acknowledged as 
minimum by the World Health Organisation (WHO) (Health Systems Trust, 2015). In 2010, the 
incidence of new RHD cases among individuals over 14 years in Soweto, South Africa was 24 
per 100,000 per year (Mayosi, 2010). A systematic review published by Zühlke et al. (2015), 
indicated that mortality caused by acute heart failure due to RHD was 25% at 60 days and 
35% at 180 days. However among patients undergoing surgery, postoperative mortality was 
2% at 30 days, and survival was 70% at 10 years, demonstrating that surgery, while expensive, 
can be a very effective intervention for RHD. On the other hand, study by Cilliers (2014) 
working in Soweto reported that number of children documented to have ARF and RHD has 
declined  from 64 in 1993 to 3 in 2010. These observations highlight that while the condition 
persists in South Africa, health outcomes are improving, undoubtedly because of 
improvements in socioeconomic conditions and available better access to primary health care 
(including surgical facilities) (Cilliers, 2014; Zühlke et al 2015). Still, improved access to 
medical and surgical treatment for prevalent cases also means high costs to the health system 
for providing chronic care. 
2. Problem Statement  
Even though South Africa is categorised as a middle income country, its healthcare system 
has been crippled by a heavy burden of disease including HIV/AIDS, TB, maternal and child 
mortality, as well as non-communicable diseases and injuries (Pereira, 2014). The pre-1994 
apartheid era created policies which were subjected to racial segregation resulting in 
dramatic health inequalities (Coovadia et al., 2009). Even now, the majority of the country’s 
households receive low-quality education and healthcare, with many restricted to 
                                                           
2REMEDY study is global rheumatic heart disease registry that collects detailed data on clinical and echocardiographic 
features both at presentation and follow-up, and accurately document clinical and echocardiographic progression of disease 
and the occurrence of disease-related adverse events, and  based in Groote Schuur and Red cross hospital, Cape Town South 
Africa” (Karthikeyan et al., 2012, Page 538).  
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impoverished living conditions and areas (Armstrong, 2006; Coovadia et al. 2009). These 
households are among the most vulnerable to diseases of poverty such as RHD (Hewitson & 
Zilla, 2010). The current Government of South Africa is in principle committed to health care 
equity and to addressing preventable infectious and non-communicable diseases. Yet RHD 
control does not appear to be a major priority on the Government’s agenda, despite its 
potential cost to the healthcare system and the loss of human capital due to disability and 
premature mortality. Unfortunately, little is known about the cost of RHD care from the 
perspective of the South African Government, which limits the public sector’s ability to 
allocate resources and assess new RHD technologies and interventions through comparative 
cost-effectiveness analyses (Irlam et al., 2015). 
3. Objectives of the Study  
The overall aim of this study is to quantify cost of care for RHD from the public health system 
(provider) perspective. In addition, this study will discuss the experience of the Department 
of Health (DoH), South Africa, since the 2005 Drakensberg Declaration on the control of 
Rheumatic Fever and Rheumatic Heart Diseases in the world. This declaration asserted that 
RF and RHD comprised greater portions of CVDs in women and children in the LMICs yet 
continued to remain largely neglected in the prevention efforts (Mayosi et al., 2006; Watkins 
et al., 2009). The specific objectives are: 
➢ estimating the average total cost of providing RHD care for patients in the public 
sector with sum of representative sample from Groote Schuur Hospital (GSH) using 
standardised costing tools and utilisation rate 
➢ quantifying variation in costs according to clinical characteristics 
➢ ascertaining whether South Africa’s health system (DoH) is/was equipped and 
prepared to engage/control RHD using data on patients diagnosed with RHD at Groote 
Schuur Hospital (GSH) in Cape Town.  
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4.  Mini Literature Review 
4.1 Epidemiology of RHD  
RHD is a lifelong illness that results in premature death for many who are affected. A 1994 
report estimated that about 12 million people suffered from RHD globally, and about 3 million 
of them experienced heart failure that needed frequent hospitalisation (WHO, 1994; Murray 
& Lopez, 1996). Many of these individuals needed costly cardiac valve surgery in interval of 5 
and 10 years (WHO, 1994; Murray & Lopez, 1996; WHO, 1997).  
Recent research estimates indicate that RHD remains a major global public health challenge, 
affecting about 33 million people across the globe with estimated 3.6 million being children 
between 5 and 14 years of age living in developing countries (Vos et al., 2016). The mortality 
rate varies between continents. For instance, in 2000, the mortality rate in Latin America was 
1.8/100,000 people compared to 7.6/100,000 people in South-East Asia (Murray & Lopez, 
1996; WHO, 2001). In addition, the mortality rate was noted as 0.5/100,000 people to 
8.2/100,000 people in Denmark and China, respectively, while in the year 2000, about 
332,000 deaths were estimated globally (WHO, 2001). That same study estimated disability-
adjusted life year (DALY) rates of 27.4/100,000 to 173.4/100,000 per year (WHO, 2001).  
Studies estimate that between 1.8 and 2.4 million African children suffer from RHD (Mayosi 
et al., 2006; Vos et al., 2016). RHD accounts for a major proportion of all cardiovascular 
diseases (CVDs) in children and young adults in African countries (Mayosi et al., 2006). The 
African continent has some of the highest prevalence rates of RHD globally. For example, 
among school-going children, 30 per 1000 were affected in Mozambique in 2007 and 15 per 
1000 were affected in Uganda in 2012 (Guilherme et al., 2007; Kennedy and Miller, 2013). 
The main socioeconomic determinants of RHD include poverty, overcrowding, low 
educational level, unemployment, malnutrition and ill equipped health systems (Longo-
Mbenza et al., 1998; Marijon et al., 2012). As a result, many LMICs still experience RHD at high 
rates, with its attendant economic burden, while wealthy nations have witnessed major 
declines in ARF and RHD over the past decades (Mishra, 2007). Several studies have 
established that the reason for the observed decline in RHD prevalence in developed 
countries included improved living conditions, presence of reliable primary health services 
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(especially to treat sore throat and prevent ARF), and advances in treatment for RHD such as 
valve surgery (Brahmadathan, 2006; Mishra, 2007; Watkins et al., 2016).  
4.2 Economic Burden of RHD 
Globally, little is known about the economic costs of RHD either from the health system or 
patient perspectives. The cost of treatment appears to vary from region to region. This is 
synonymous with the findings by Terreri et al. (2001). For instance, per-patient cost of care in 
United States of America (USA) was about $6000 in 2002 (Saslaw et al., 1965; Ehrlich et al., 
2002), while per-patient cost in China was about $4700 in 2012 (Wang et al. 2015). One study 
in Cuba indicated that the cost of severe RHD care was about $6300 (Watkins et al., 2015) in 
the 1990s, while the cost burden per-patient in South Africa for only inpatient treatment was 
$2900 (about ZAR35, 000) in 2010 (Irlam et al., 2013). 
Developed countries face the highest per-patient cost of RHD given that these countries have 
higher prices and greater utilisation of advanced medical care than the LMICs. At the same 
time, the economic impact of RHD is felt more to LMICs health systems because of the much 
higher numbers of cases and more limited resources. Most African children and adults with 
RHD have lost opportunities for prevention because of low resource allocation towards 
preventive interventions such as treatment of sore throat (Cilliers, 2015). The consequence 
of this misallocation to patients and health systems is the high cost of irreversible heart valve 
damage that can only be alleviated by surgery, if it is available at all (Gunter, Asmera & Parry, 
2006; Watkins et al., 2016).  
In addition to its cost to health systems, RHD probably affects households due to catastrophic 
and impoverishment impact resulting from high out-of-pocket payments to access care. 
Globally, over 100 million individuals are pushed into poverty and more than 150 million 
individuals suffer from excessive out-of-pocket healthcare payments (WHO, 2013). 
Cardiovascular diseases, which are generally a low priority for public finance in many 
countries, tend to result in catastrophic health expenditures at very high rates (Huffman et 
al., 2011). Yet we have very little direct evidence for the economic impact of RHD on patients, 
with only one study to date (in Brazil) devoted to this topic (Terreri et al., 2001). Hence in 
countries where the health system is ill equipped and under-financed, RHD can reinforce the 
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“poverty trap” by incapacitating poor people with high out-of-pocket payments (McIntyre et 
al., 2006). In addition, many school age children drop out of school as a result of RHD, 
including 67% of affected children in Nigeria (Yilgwan, Olge & Bode-Thomas, 2014). These 
factors can, in turn, hamper economic growth and development (Robertson & Mayosi, 2008).  
4.3 Health Systems and RHD  
The high medical costs of RHD, including heart surgery, leave many people without access to 
needed care (Gunter, Asmera & Parry, 2006; Wang et al. 2015). Additionally, health systems 
in LMICs are often unable to deliver RHD prevention and treatment interventions at 
acceptable coverage rates (Moloi et al., 2016). Prevalent barriers to care include inadequate 
community awareness, limited health literacy, insufficient health-seeking conduct, and 
absence of health care treatment options that are available, affordable and acceptable 
(Zuhlke et al., 2015; Moloi et al., 2016). Given these barriers and budgetary constraints, it is 
crucial for public health systems to address these constraints in a contextualised and 
economically efficient manner (Longenecker et al., 2014).  
Given that RHD affects the poor, the cost burden often falls on the government to provide 
health services in public facilities – for instance, to 80% of the population in South Africa 
(Koch, 2011; Ataguba, 2012). Yet RHD treatment is very expensive; one group estimated the 
cost of replacing one heart valve at $4, 145 (ZAR50, 000) (The heart and stroke foundation 
South Africa, 2016). Furthermore, individuals who have undergone surgery face additional 
challenges that may require more heart operations, making them more susceptible to 
complex, lifelong heart problems and their attendant costs (Marijon et al., 2012). These 
challenges have probably forced public health facilities to limit the number of valve surgeries 
that can be performed. As a consequence, many South Africans die while awaiting valve 
surgery (Zilla, 2014). Again, many of these costs can be prevented by increasing coverage of 
sore throat and ARF interventions and thus preventing RHD; in Cuba, expenditure on heart 
surgery fell by about 90% within a decade following a comprehensive RHD prevention 
program (Watkins et al., 2015).  
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4.4 Cost Analysis 
Full economic evaluation comprises four types of approaches: cost-effectiveness analysis 
(CEA), cost-utility analysis (CUA), cost- benefit analysis (CBA) and cost minimisation analysis 
(CMA) (Drummond et al., 2005). It is often defined as a systematic approach, which is utilised 
to compare and contrast two or more interventions on a basis of costs and outcomes 
(Drummond et al., 2005). Other economic analyses only deal with the initial (first) section of 
an economic evaluation; these are called cost analyses (Creese & Parker, 1994). The cost 
analysis approach is often used in disease-specific studies to assess the cost of providing 
health care.  On the other hand, the cost analysis approach does not assess outcomes, so it is 
considered as partial economic analysis approach (Creese & Parker, 1994; Drummond et al., 
2005). When there are no data on interventions for a specific disease, researchers and policy 
makers can use cost analysis, particularly in areas that have not been explored before. A cost 
analysis of RHD in South Africa, for instance, may spur greater interest on the part of 
Government in developing interventions, and the costs can also serve as inputs for future 
economic evaluations. 
The literature on the cost of adult cardiovascular diseases (CVDs) is much larger than the 
literature on RHD that was reviewed above. Studies have generally been conducted from the 
perspective of the patient or of the health system; recently Jaspers et al. (2015) reviewed the 
former, and Brouwer et al. (2015) reviewed the latter. Of note, the combined perspective of 
all parties, including both patients and providers, is referred to as the “societal” perspective, 
yet few CVD costing studies in LMICs have combined the two perspectives. 
Costs can also be decomposed into direct and indirect components. Drug costs, Laboratory 
test costs, and consultation fees are examples of direct components, whereas time off work 
due to illness is an example of an indirect cost (Drummond et al. 2005). Studies of costs from 
the health system perspective typically do not consider indirect costs, which are largely borne 
by patients. Provider costs are commonly obtained from assessing medical records to 
understand the quantities of resources typically required to deliver care (Ivanova et al., 2009) 
and surveying health facilities to capture prices of all healthcare inputs (Hendriks et al., 2014).  
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When performing disease-specific cost of care, cost items can be valued using two 
approaches: ingredients (bottom-up) and top-down. Which approach to use is a key decision 
in costing that affects the costs and the resources required to conduct the study (Cunnama 
et al., 2016). The ingredients approach uses detailed action and input utilisation data from 
records (or observed utilisation) to estimate unit costs at the service provider level (Batura et 
al., 2014; Cunnama et al., 2016). The step-down approach uses formulae that allocate overall 
expenditure to each and every input/ingredient to determine unit costs (Cunnama et al., 
2016). 
Studies comparing both costing approaches suggest that the ingredients approach is likely to 
be more precise because it captures resources more comprehensively (Hendriks et al., 2014). 
The data needed for the ingredients approach can be easier for access compared to the step-
down approach, even though the former is specific to a setting, more time demanding, and 
more expensive to carry out (Simoens, 2009). A study based in the United States further 
analysed importance of both costing approaches and highlighted strength of either approach. 
The study established that ingredients approach was better able to capture site-level 
differences, whereas the step-down approach was better able to capture national long run 
average costs (Chapko et al., 2009; Cunnama et al., 2016).  
5. Study Methods  
5.1 Study Design 
This study will be a cost analysis of RHD from the provider (health system) perspective using 
a combination of bottom-up and step-down costing, similar to other studies (settumba et al., 
2015). This will be a cross-sectional study that seeks to assess the average total cost of care 
in the Western Cape based on a typical patient mix at referral healthcare facility. All costs will 
be estimated in 2017 South African Rand (ZAR). 
5.2 Study Setting 
The study will sample patients receiving care for RHD at the Groote Schuur Hospital (GSH), 
situated in Cape Town, Western Cape, South Africa. Particularly, patients will be recruited 
from the REMEDY registry database that collects detailed data on clinical and 
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echocardiographic features both at presentation and follow-up with a total of about 500 
study participant patients.  
5.3 Sample Size 
This study is cost analysis from the health system perspective at tertiary level. A random 
sample of 100 patient medical records from REMEDY study participants will be used for the 
study.  We aim to estimate cost of advanced tertiary level provision of RHD treatment using 
the entire sample size (100 patients).  
Given that the proposed study is in its pilot phase, we plan to recruit more participants in the 
sample if we are underpowered or need greater precision in any particular estimates. A 
previous study estimated the cost of average inpatient3 RHD care as $2900 (ZAR35 000) with 
a variance of $800 (+/- 25% or so) (Irlam et al 2013). We therefore assume that a sample of 
100 patients will provide a 5% margin of error on the estimated mean cost and will likely be 
adequate for estimating the total cost of care as proclaimed by Irlam et al (2013).  
6.  Assessing RHD Costs from the Health System Perspective  
In this study we will categorize and quantify health system-related costs of RHD to answer 
the question, “What is the average cost of providing RHD care in current practice?” We use 
medical records of the sampled participants to look at resource utilisation over the previous 
year, including inpatient and outpatient costs. The components of direct costs will include 
administrative costs, healthcare worker salaries, emergency medical services, pharmaceutical 
costs, diagnostic tests, physiotherapy, and others (Nordin et al., 2012). In addition, so-called 
“overhead” costs (which some researchers also call “indirect costs”) will be assessed; these 
include utilities and maintenance, rent, consumables, housekeeping services, and others. We 
will use a series of data collection forms (survey instruments) to capture the relevant 
information from participant medical records and from facility records. In all instances we will 
estimate economic costs of RHD care. Unlike the financial costs that accounts the actual 
expenditure of goods and services, the economic costs accounts for cost of all inputs, even if 
                                                           
3 The study basis of the assumption for average inpatient cost of RHD care was; daily intramuscular penicillin 
plus 1 set of laboratory tests/electrocardiography/echocardiogram/chest x-ray.  
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these were provided for free including the value of the next best alternative foregone (i.e. 
opportunity cost) as a result of the use of resources (Conteh & Walker, 2004; Drummond et 
al., 2005). Estimating the opportunity costs of resources will allow us to account for worth of 
resources which are donated and/or voluntarily offered (i.e. money, materials or labour).  
6.1 Estimating Overhead Costs Using the Step-Down Approach 
The step-down costing method will be used to account for overhead costs of providing RHD 
care, including both recurrent and capital costs of the health facilities. While recurrent costs 
are resources with valuable lifetime of less than one year, capital costs are resources that 
have lifetime of more than one year (Hansen et al., 2010). In essence, the step-down approach 
will capture the cost of running GSH in order to provide RHD care directly (Drummond et al., 
2005; Free et al., 2013). The step-down costing approach was explained in detail by Conteh 
and walker (2004), who summarised seven stages of step-down costing (Figure 1). 
Figure 1: Summarised stages of step-down costing (Adapted and edited from Conteh and walker, 
2004) 
 
 
12 
  
Conteh and walker (2004) also demonstrated that estimating costs within the health facility 
tier (i.e. indirect, intermediate and direct) should reflect flow of each cost centres resources. 
In order to capture all the costs incurred, we will divide various departments of GSH into final, 
intermediate and overhead cost centres. 
Final refers to the departments that directly provide medical services to patients (Creese & 
Parker, 1994; Drummond et al., 2005) - in this study, outpatient and inpatient cost 
departments are the final cost/resource departments of this costing study.    
Intermediate refers to the departments that render support services to the final 
cost/resource departments. These are drugs or/and diagnostic services which are often 
supported by pharmacy units or/and laboratory within the healthcare facility.  
Overhead cost centers refers to general service support providing cost units that are crucial 
for the hospital to operate such as administration, maintenance and cleaning (buildings, 
laundry and linen) (Creese & Parker, 1994; Afriandi et al., 2010). The overhead cost centres 
render services to the entire hospital, so we will perform their cost first during step-down 
procedure costing. These will be followed by costing of intermediate departments, and the 
final cost departments will be estimated at the end. In summation, the cost of intermediate 
and overhead departments is allocated to the final cost department in a sequential manner.   
The standard step-down methodology will be applied once the cost centres and departments 
have been identified (Hansen et al. 2000). In order to figure out the RHD cost in a stepwise 
manner, we will assign recurrent and capital costs to the various cost centres directly 
depending on their actual resource utilisation. A typical example will be the salary cost of 
administrative personnel, which will be assigned to the cost of administration centre, while 
the outpatient department salary cost of nurse depends on a proportion of time that the 
nurse spent in the outpatient department. Once all recurrent and capital costs have been 
assigned to various cost centers, the subsequent step will be assigning the overhead costs to 
intermediate and later to final cost centre.  
The final step involves assigning the cost of running intermediate cost centres to the final 
centres. After completing the cost allocation to their respective final cost centres, we will 
divide the total cost of the outpatient department to the total number of outpatient visits in 
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order to obtain the unit cost per outpatient visit. Thus the total cost of RHD care from health 
care system perspective will be addition of the unit cost per outpatient visit (calculated using 
step-down approach) and average medical cost per person (calculated using the ingredients 
approach).  
Data from the most recent financial records will be obtained. In a situation where financial 
records such as data on staff costs are absent, we will establish list of the employees who 
work in the department of concern and their salaries will be billed according to their salary 
rates. However, inventory list will be made available to capture capital goods (buildings, 
furniture and vehicles) if data is not available in this regard.  
Capital costs will only be valued depending on their respective replacement costs. As 
demonstrated by Drummond et al., (2005) capital goods will be annualised using a discount 
rate of 3% in order to allow the depreciation and opportunity cost of goods (i.e. buildings, 
furniture, vehicles) purchase. The lifetime of these capital goods vary according to their 
categories. The estimated lifetime is generally 30 years for buildings, 10 years for furniture, 
and 5 years for vehicles (Creese & parker, 1994; Drummond et al., 2005). When performing 
the sensitivity analysis we will use 0%, 5% and 10% discount rate. 
6.2 Estimating Direct Medical Costs Using the Ingredients Approach  
Data on direct medical costs will be collected from medical records of the participants. We 
will review 100 medical records to determine service utilisation over the past year. 
Information on demographic characteristics, number of visits, attendance, diagnostics, and 
amount of medication dispensed to each participant will be collected from REMEDY study 
case report forms. Direct but non-participatory observation will be performed in order to 
establish the patient-provider interaction process (i.e. duration of patient-provider contact). 
Structured interview with one the staff involved in the RHD patients treatment will also be 
done in order to obtain information regarding various activities performed as well as the 
length of time spent on each activity. For each study participant, we will estimate the total 
direct medical cost of care as the sum of the cost of all the individual components of care 
described above. Each of these components will be costed by multiplying the quantity of 
resources consumed over the past year by the relevant price. In order to achieve this, we will 
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tabulate all RHD-related resources consumed over the past year for each patient as has 
already been recorded in their REMEDY case report forms. Prices will be obtained for all 
inpatient and outpatient goods and services from GSH separately. A brief overview of the 
costing methods and data requirements is provided under Appendix A. 
7. Data Analysis 
Raw data in the data collection instruments will be reviewed by a separate study member and 
verified and checked for errors. The study data will then be entered into Microsoft Excel 
(Microsoft Corporation, USA) for quality evaluation as well as performing analyses.  
8. Sensitivity Analysis 
While performing economic evaluations, number of assumptions or parameters are made 
and incorporated into the analysis. Consequently they cause uncertainties that may influence 
the results. One-way deterministic sensitivity analysis will be conducted in order to address 
such uncertainties, and to ensure the outcomes of this study are robust and comparable 
across different studies. Further, conducting sensitivity analysis will allow us to evaluate the 
uncertainty of our findings while allowing for generalizability to other research settings 
(Walker & Fox-Rushby, 2001). For this study, we will focus on the impact of major assumptions 
such as discount rates and utilisation rates of the clinical units (which we will collect by direct 
observation then apply uniformly to all participant data) evaluated one parameter at a time.  
9. Ethical Considerations 
This study will collect primary data on costs from the health facility and will conduct 
secondary analysis of medical records to obtain types and quantities of resources consumed 
in providing RHD care. The study entails minimal risk to patients and providers, and all 
participant data will be obtained in a de-identified format. First of all we will not record any 
personal/identifiable information of the patients. Second of all, this study is sub-analysis of 
REMEDY study that previously obtained ethical approval (HREC reference number 028/2006). 
However, ethical approval will be obtained from the Human Research Ethics Committee 
(HREC) of the University of Cape Town (UCT) prior to the beginning of the study.  
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PART B: LITERATURE REVIEW 
The aim of this section is to critically appraise the theoretical, methodological, and empirical 
literature focused on Rheumatic Heart Disease (RHD) and its economic burden on health 
systems.  It will also identify the current gaps in the literature regarding the RHD burden in 
South Africa. 
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1. Theoretical Background of RHD  
1. 1 Epidemiology of RHD 
Heart valves assist the movement of blood through the chambers of the heart with each and 
every heartbeat. A disease that damages these heart valves, causing its failure to open and 
close normally, resulting in blood moving in the wrong direction, is called Rheumatic Heart 
Disease (RHD actions, 2017). It is also characterised as chronic inflammatory disease of the 
heart valves, and is primarily a disease of childhood and adulthood that results from recurrent 
incidences of acute rheumatic fever (ARF) (Moloi, et al. 2015). The main cause of ARF is 
untreated group A streptococcal (GAS) pharyngitis, causing a sore throat (Mayosi, et al. 2006; 
Beaton, et al. 2012; Zuhlke, et al. 2015). Streptococcal pharyngitis is an infection of the back 
of the throat including the tonsils with symptoms such as fever, sore throat and red tonsils 
(Ehrlich, et al. 2002; Carapetis, et al. 2005). However, RHD is a preventable disease if GAS 
pharyngitis is treated by means of benzathine penicillin that is an antibiotic which is useful for 
the treatment of a number of bacterial infections (Mayosi, et al. 2006; Watkins, 2015). Further 
occurrence and severity of the disease can be minimised through treating the patients with 
prophylactic penicillin in order to prevent additional cardiovascular damage (Godown, et al. 
2015).  
Despite its preventability, a large number of learners miss out on the opportunity to avert 
RHD by not presenting themselves to care before advanced heart failure occurs (Godown, et 
al. 2015; Zuhlke, et al. 2015). The main reason for patients not seeking healthcare can be the 
epidemiology of RHD in that it is usually dormant in its premature stages or during early 
childhood years (Zuhlke, et al. 2015). Most recent estimates indicate that there are 33 million 
people who suffer from RHD globally, with about 320,000 deaths in 2015 (Naghavi, et al. 
2015). RHD sequelae include heart failure, as well as arrhythmias, stroke and infective 
endocarditis (Watkins, 2015). Most of these sequelae affect young school-going children and 
economically dynamic and childbearing adults (Araújo, et al. 2012). These conditions in turn 
lead to gradual disability, loss of quality of life and eventually premature death (Kumar & 
Tandon, 2013).  
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Unsurprisingly, high prevalence of RHD is mostly witnessed within nations from Africa, South 
Asia, and the Pacific Islands (Beaton, et al. 2012). Specifically, sub-Saharan Africa, South-
central Asia, the Pacific and indigenous populations of Australia and New Zealand are worst 
affected (Mayosi, 2010; Seckeler & Hoke, 2011). These nations often struggle to tackle 
epidemic such as RHD as a result of inadequate resources. This is because RHD management 
requires policies that adequately recognise and devote resources towards its prevention and 
control (Mayosi, 2010; Moloi, et al. 2017). Failure to devote the required resources in order 
to tackle the RHD burden leads to severe conditions of the disease and it cripples the heart 
valves, causing heart failure and eventually premature death (Carapetis, et al. 2006; Zühlke, 
et al. 2015). Once it severely damages the heart valves, surgery is often required to repair or 
replace the valves of patients (Mayosi, et al. 2006). Surgery reduces the challenges and 
prolongs the life of the patients yet the cost is very high, and its burden on the healthcare 
sector resources is enormous (Carapetis, et al. 2006; Hewitson & Zilla, 2010).   
1.2 RHD Disease Estimates 
Low and middle income countries (LMICs) witnessed a decline in communicable disease, and 
thus mortality rates in children under-five, by more than a half between 1990 and 2015 after 
focusing on the implementation of millennium development goals (Curry, et al. 2017). 
However, studies suggest that further attention is required to reduce mortality and morbidity 
caused by neglect and non-communicable diseases (NCDs) (You, et al. 2015). One of the 
preventable and treatable forms of a disease that requires early detection, screening, 
diagnosis and treatment is RHD (Watkins, 2015; Zühlke, et al. 2015). However, RHD has been 
neglected for decades and it is a common cardiovascular disease (CVDs) in developing 
countries (Watkins, 2015; Moloi, et al. 2017). People living with RHD in developing countries 
account for about 80% of the disease, with the rest living in susceptible communities in 
developed countries (Robertson & Mayosi, 2008; Global Burden of Disease (GBD), 2013). Of 
this figure, more than 60% of school–aged patients drop out of school due to hindrances that 
RHD imposes, thus preventing them from realising their full potential (Yilgwan, et al. 2014).  
RHD is one of the neglected NCDs, and its presence persists in LMICs (Moloi, et al. 2017). Lack 
of progress on addressing social determinants such as overcrowding, sanitation, nutrition, 
healthcare and awareness of the disease as a result of prolonged poverty in LMICs has been 
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an obstacle to fighting GAS, and thus addressing RHD (Curry, et al. 217). Studies have 
established that the prevalence of the disease is much higher in children of school-going age 
and young females of childbearing potential (Manji, et al. 2013).  
The global RHD Registry (the REMEDY study) findings also stipulated that those affected by 
RHD are predominantly young, unemployed and female from backgrounds dominated by 
poverty and social injustice (Carapetis, 2007; Zuhlke, et al. 2015). These include poor access 
to primary healthcare as the main barrier to implementing primary and secondary 
preventions against rheumatic fever in most of the LMICs (Watkins, 2015). As a result, 
numerous patients present themselves late in the disease sequence of established RHD 
(Carapetis, et al. 2016). LMICs also face factors that arise from their health systems, such as a 
shortage of resources for health care, inadequate expertise of healthcare workers and low 
awareness of RHD within the communities causing Inadequate (misdiagnosis or late 
diagnosis) treatment of RHD (Bronze, 1996; Mayosi, et al. 2006).  
Currently, 2.4 million children aged between 5 and 14 out of 3.6 million affected globally 
reside in developing countries (Vos, et al. 2016). On the other hand, developed nations have 
witnessed major declines in ARF and RHD over the past decades (Mishra, 2007). The reason 
for the observed decline include improved living conditions, the presence of reliable primary 
health services (especially to treat sore throat to prevent ARF) and advances in the treatment 
of RHD, such as valve surgery (Brahmadathan, 2006; Mishra, 2007; Watkins, et al. 2016). Also, 
between 1.8 and 2.4 million African children suffer from RHD (Mayosi, et al. 2006; Vos, et al. 
2016).  
Africa is one of the highest affected continents, with the sub-Saharan Africa (SSA) region 
having the most estimated prevalence of RHD among school children (Mayosi, et al. 2006; 
Cilliers, 2015). SSA, which is home to only 10% of the world’s population, is thought to account 
for 50% of children who suffer from RHD (Ntusi & Mayosi, 2009). The main socioeconomic 
determinants are poverty, overcrowding, low educational level, unemployment, 
malnutrition, and ill-equipped health systems (Longo-Mbenza, et al. 1998; Marijon, et al. 
2012). As a result, countries such as the Congo, Mozambique and South Africa still experience 
high rates of RHD, with its attendant economic burdens (Mishra, 2007).  
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School-based studies in Mozambique indicated that the RHD prevalence in children is as high 
as 30 per 1000 (Marijon, et al. 2007) while incidence of new RHD cases among individuals 
over 14 years in Soweto, South Africa was 24 per 100,000 per year (Mayosi, 2010). Studies 
have found that 1 in 5 African children with RHD die by the age of 15, and 1 in 5 of them die 
by the age of 25 (Kimbally-Kaky, et al. 2002; Oli & Asmera, 2004). A systematic review 
published by Zühlke, et al. (2015), indicated that mortality caused by acute heart failure due 
to RHD was 25% at 60 days and 35% at 180 days. However among patients undergoing 
surgery, postoperative mortality was 2% at 30 days, and survival was 70% at 10 years, 
demonstrating that surgery, while expensive, can be a very effective intervention for RHD. 
1.3 Economic Burden of RHD 
The prevalence of RHD in LMICs amongst the children and young adults imply huge economic 
effects (Mayosi, 2010).  Such effects hinder a country’s growth through excessive direct and 
indirect healthcare costs at both the individual and national levels (Terreri, et al. 2001; WHO, 
2004; Hewitson & Zilla, 2010). The estimated economic and financial burden of RHD in low-
income countries is believed to be a million times higher ($56 billion) than the funds obtained 
from donors, and it requires an increase in public and private sector spending for effective 
prevention and control of the disease (Watkins, 2015; Watkins & Daskalakis, 2015). To 
mitigate these challenges, global research and development funding allocated $1.7 million to 
RHD, that was only 0.1% of the global health fund for RHD in 2015 (Watkins % Daskalajis, 
2015). However, lack of information regarding the costing and accurate clinical data have 
been said to be the main issues for funds to be distributed in low-income countries as per 
need (Mayosi, 2016; Shung-King, et al. 2016). In addition, lack of evidence for a more 
appealing plan, such as a return on investment to prevent deaths related to RHD, hindered 
the scaling up of expensive medical and surgical interventions in the region (Watkins & 
Daskalakis, 2015).  
Surgical interventions impose high and irreversible costs on the health systems since severe 
RHD conditions can only be alleviated by surgery, if it is available at all (Gunter, Asmera & 
Parry, 2006; Watkins, et al. 2016). Still, the improved access to medical and surgical treatment 
for prevalent RHD cases also means high cost to the health systems for providing chronic care. 
High costs for RHD can also reinforce the “poverty trap” by incapacitating poor people with 
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high out-of-pocket payments (McIntyre, et al. 2006). On the other hand, the loss of young 
adults, which are the most productive and childbearing adult portion of the population, in 
turn undermines the national productivity of these countries (Araújo, Goulart & Meira, 2012). 
These factors can, in turn, hamper economic growth and development (Robertson & Mayosi, 
2008). Furthermore, the management of the RHD burden could also pose enormous effects 
through exacerbating the existing inequalities in healthcare access and delivery for 
disadvantaged people in developing countries (Katzenellenbogen, et al. 2017).  
If one takes a lesson from the available empirical evidence on CVDs, it is clear that the RHD 
burden affects health systems and hampered GDP by affecting households due to a need for 
out-of-pocket payments to access care. This is because CVDs, which are generally a low 
priority for public finance in many low-income countries, tend to result in catastrophic health 
expenditures at very high rates (Huffman, et al. 2011). This cost could also arise from patients 
paying for transportation and/or missing or losing jobs as a result of the disease. Yet we have 
no evidence for the economic impact of RHD on patients, with only one study to date (in 
Brazil) devoted to this topic (Terreri, et al. 2001). In countries where the health system is ill 
equipped and under-financed, RHD possibly heighten the level of poverty (McIntyre, et al. 
2006). This was intensified by the lack of access to evidence-based interventions in the regions 
(WHO, 2004; Watkins, 2015). Therefore, it is clear that LMICs need interventions and 
programmes to prevent and control RHD. 
1.4 Interventions to prevent and treat RHD 
RHD became rare in developed countries because of effective interventions that were put in 
place. Evidence indicates that countries such as Australia, New Zealand and the USA have 
seen huge declines in disease incidence, largely by using penicillin for primary prevention 
(Carapetic, 2007). Improved living conditions and better hygiene reduced overcrowding while 
malnutrition, also contributed towards the decline of the disease (Carapetic, 2007). The 
consequence of this decline has seen parallel Reduction in RHD related research and left the 
LMICs to tackle the burden on their own. Therefore, LMICs need to draw a lesson from the 
developed world regarding potential preventative and treatment measures to fight RHD. 
Table 1 illustrates the interventions and preventative measures recommended by the World 
Health Organization (WHO) (WHO, 2004).    
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Table 1: Potential Preventive Measures of ARF/RHD 
Interventions/preve
ntative measures 
ARF/RHD 
          Description Potential outcomes of the 
intervention/preventative 
measures of ARF/RHD 
Primordial 
prevention 
Having improved environmental 
conditions and access to resources 
that improve living conditions  (i.e. 
clean housing, hygiene, nutrition, 
sanitation and overcrowding) as well 
as other social determinants of 
health (i.e. employment, education 
and infrastructure) 
Reduces risk factors for 
Group A streptococcal (GAS) 
infections (strep throat)  
Primary prevention Effective screening using 
echocardiography, diagnosis and 
treatment of strep throat at the 
primary level of care 
Prevents the initial attack of 
acute rheumatic fever (ARF) 
Secondary 
prevention 
Administrating people with a history 
of rheumatic fever with antibiotics 
(specifically preventing with  
benzathine penicillin) to avoid GAS 
infection  
Minimizes subsequent ARF 
recurrence and progression 
of ARF to RHD  
Tertiary prevention  Proving advanced medical and 
surgical care such as heart valve 
replacement/surgery and  
medications  
Manage cardiac heart 
failure, prevent stroke, 
reduces chances of 
premature death 
From the potential ARF/RHD prevention measures illustrated above, secondary prevention 
programmes have proved to be cost-effective and practical even in the poorest countries 
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(Carapetic, 2007; Irlam, et al. 2013). Available empirical literature also underscores the fact 
that the secondary prevention programmes are mostly cost-effective and efficient compared 
to the notions of primary prevention programmes (Michaud, et al. 1999; Manji, et al. 2013). 
This is because primary prevention is believed to be effective in well-resourced settings and 
less practical in LMICs where disease rates are high and the health system is ill-equipped 
(McDonald, et al. 2005). Several studies also highlighted the importance of reducing 
hospitalisation and surgery by utilising antibiotics (secondary prevention) while advocating 
for integration of existing primary healthcare systems in order to eliminate the cost burden 
of RHD (Nordet, et al. 2008; Watkins, et al. 2015).  
1.5 Country Profile - South Africa 
1.5.1 Demographic and Economic Features of South Africa 
According to the World Bank estimates of world economies, South Africa is a middle-income 
country with an abundant supply of natural resources (World Bank, 2014). The country’s 
population estimate for 2015 was 56 million with 12 million of the population living in 
extreme poverty (Statistics SA, 2014). High levels of poverty imply a high burden of healthcare 
expenditure for the government, with the National Department of Health (NDoH) holding 
general accountability (Koch, 2011; Ataguba, 2015). In addition, the prevalence of 
unemployment, poverty and inequality in South Africa has been accelerated in recent years 
by lowered economic growth, slowing to 0.4% in 2016 (National Treasury SA, 2017). While 
the high unemployment rate persists, due to the negative effects of slow economic growth 
rate, the government continues to focus on controlling inflation (South African Reserve Bank, 
2017); yet, the country continues to face structural challenges (i.e., shortage of skills, frequent 
stoppages of work because of strikes and a decrease in global competitiveness) which, in turn, 
constrain economic growth (Van Broekhuizen, 2016). As a result, the current government 
faces increased pressure from the listed challenges, while the economic outlook is also 
expected to remain slow (Van Broekhuizen, 2016; National Treasury SA, 2017).      
 1.5.2 Health System Context and Structure of South Africa 
South Africa's health system comprises of a large and fast growing public sector, but smaller 
private sector, and non-government organisations (NGOs) (Jobson, 2015). The country has 
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4200 public sector facilities with 13, 718 individuals on average receiving treatments from 
each clinic (Bekker, et al. 2014). The facilities host 2.5 visits from people on average each year 
with bed occupancy rate in hospitals being between 66% and 77% (Jobson, 2015). The public 
sector utilises 11% of the total government budget which is more than the 5% recommended 
by WHO (McIntyre & Thiede, 2006). South Africa has poor health outcomes despite this high 
government expenditure, replicating greater inequality within the healthcare compared to 
other middle-income countries (Bekker, et al. 2014; Ataguba, 2016). It is also believed that 
the quality of the public sector healthcare provision is hindered by a shortage of crucial 
medical personnel (International Council of Nurses, 2006; Wyber, et al. 2014).  
 1.5.3 Healthcare Provision and Financing in South Africa 
Besides the challenge of heavy burdens from NCDs and communicable diseases, the 
healthcare provision and financing in South Africa is controversial and inequitable, while 
about 12 million people live in extreme poverty (Statistics SA, 2014). While formally employed 
and those which are well-off obtain healthcare from private and public sector, poor is limited 
to the inadequate and underfunded public sector healthcare (McIntyre & Thiede, 2006). Even 
though the government has embarked on a National Health Insurance scheme, it has a long 
way to go before it provides equitable healthcare access (McIntyre, et al. 2014). Currently, 
about 80% of the population depends entirely on the public sector for all health services, 
while heavily subsidised private healthcare and inpatient care is available for merely 16% of 
the population (Ataguba, et al. 2011). In the meantime, the public health system carries an 
inevitable financial burden, and hence inefficient and inadequate care has been provided for 
the majority of the population, specifically the poor who are exempt from service payments 
or user fees when seeking care in the public sector (Ataguba & McIntyre, 2012). In addition, 
the poor also encounters out-of-pocket non-medical cost payments such as transport and 
food when confronted by largely preventable but neglected diseases (Douglus & Modie, 
2016). In South Africa, out-of-pocket healthcare payments contribute 13.78% of overall 
health sector expenditure while government contributes about 44%, and medical schemes 
covers 42% (Ataguba, 2012; Nicolson, 2015). This is relatively high for a middle-income 
country such as South Africa when compared to 0.5% in low-income countries such as Sudan 
and Djibouti, signifying that out-of-pocket payments relative to government expenditure 
deserve attention in South Africa (McIntyre and Kutzin, 2011).  
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1.6 Epidemiology of RHD in South Africa 
In 2010, the incidence of new RHD cases among individuals over 14 years in Soweto, Gauteng 
was 24 per 100,000 per year (Mayosi, 2010). A systematic review published by Zühlke, et al. 
(2015), indicated that mortality caused by acute heart failure due to RHD was 25% at 60 days 
and 35% at 180 days. However, the same study reported that among patients undergoing 
surgery, postoperative mortality was 2% at 30 days, and survival was 70% at 10 years, 
demonstrating that surgery, while expensive, can be a very effective intervention for RHD. On 
the other hand, Cillers (2014) working in Soweto reported a decline in the number of children 
with ARF and RHD visiting to Chris Hani Baragwanath Hospital in Soweto, South Africa from 
1993–2010. Yet, a echocardiographic screening study of school-children in Cape Town 
revealed a prevalence of hidden RHD of 20-30 per 1000, as well as changing patterns of the 
disease (Engel, et al. 2015). Shung-King, et al. (2016) revealed that 50% of these cases alter to 
normal if followed up for 5 years. South African Cardiovascular diseases (CVDs) guidelines 
recommend for areas, where there is a RHD epidemic, that all cases of sore throat in children 
between 3 and 15 years of age should be treated as streptococcal infection (Mayosi, et al. 
2010).  
The high burden of RHD related heart failure and mortality, as mentioned in a study by Zühlke, 
et al. (2015), and demonstrated in Soweto recently, have declined in South Africa since 1997 
(Mayosi, 2016). These observations highlight that, while the RHD condition persists in South 
Africa, health outcomes are improving, undoubtedly because of the  ‘Mandela dividend’ 
associated with socioeconomic improvement, and enhanced access to primary health care 
(including surgical facilities) (Zühlke, et al. 2015). Still, improved access to medical and surgical 
treatment for prevalent cases also means high costs to the health system for providing 
chronic care.   
This costly disease was made a notifiable condition in October 2005 during the 1st Pan-African 
conference on ARF and RHD hosted by the National Department of Health (NDoH) of South 
Africa (Mayosi, 2016). During this conference, a clarion call to African governments and their 
ministries of health was made to adopt programmes to abolish ARF and control RHD by 
increasing awareness, surveillance, advocacy, and prevention (ASAP) was adopted (Engel, 
2012; Mayosi, 2016). The adoption of these programmes was followed by the Addis Ababa 
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Communiqué in June 2015, when African heads of states endorsed seven action plans to 
address the obstacles to RHD control that were acknowledged in the REMEDY study (Zühlke, 
et al. 2015; Watkins, et al. 2016). It is believed that South Africa has the required conditions 
to successfully eradicate ARF and RHD (Mayosi, 2016). The NDoH launched the National 
Rheumatic Fever Week, labelling ARF amongst notifiable conditions in an effort to improve 
access to primary healthcare (NDoH, 1997; Mayosi, et al. 2006). However, healthcare 
practitioners also need to be trained in order to notify ARF cases, utilise the electronic registry 
to capture the new patients with sore throat and treat them with penicillin as the South 
African ARF/RHD guidelines (South African National Department of Health, 1997; Mayosi, 
2016). RHD community has relatively small amount of advocates, clinicians and researchers 
compared to the enormous group of stakeholders in large disease communities (i.e., 
TB)(Wyber et al., 2014). However, investigating the impact of these conditions that are 
believed to hasten the demise of ARF/RHD in South Africa is crucial.  
2. Methods for Estimating Healthcare Costs 
2.1 Economic Evaluation in Healthcare   
Consumer economics assumes that consumers make choices intended at maximising their 
level of satisfaction, and that optimal choices are made once the consumer has been provided 
with full information (Cunningham, 2000; Drummond, et al. 2005). However, persons who 
present themselves for health care are often unable or reluctant to provide the required 
information that will enable them to exercise their choice to access health care (Ataguba, 
2012). This consumer side of failure is further complicated by the fact that the person 
supplying the needed information to the prospective patient is the very same person 
supplying treatment which does not occur in other fields, but in the healthcare sector 
(Cunningham, 2000; Tenkorang, 2016). Because of this, allocating healthcare resources in an 
efficient and equitable manner has always been a controversial matter (McIntyre & Kutzin, 
2011; Ataguba, 2012). As a result, economic evaluation in healthcare has become more 
important in recent years, and now it is an accepted tool for the appraisal of healthcare 
programmes (i.e. health financing policies) (Chisholm & Evans, 2007).  
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Full economic evaluation includes four types of approaches: cost-effectiveness analysis (CEA), 
cost-utility analysis (CUA), cost-benefit analysis (CBA) and cost minimisation analysis (CMA) 
(Cunningham, 2000; Drummond, et al. 2005). Economic evaluation is often defined as a 
systematic approach, which is utilised to compare and contrast two or more interventions on 
a basis of costs and outcomes (Drummond, et al. 2005). In particular, CEA compares and 
contrasts alternative interventions versus primary objectives of the programmes in order to 
estimate the level of reduction in morbidity and/or life years saved in natural units (Frick, 
2007). CUA compares similar interventions as CEA but utilises more broad outcomes such as 
quality-adjusted life years (QALYs) and disability-adjusted life years (DALYs) measured directly 
from patients (Drummond, et al. 2005; Frick, 2007). It is a preferred approach when 
evaluations comprise numerous objectives within the programmes, and both quality and 
quantity of life are vital outcomes (McCabe, 2009). CBA compares interventions using broad 
monetary outcomes (i.e. Rands) and differs from CUA because it values health outcomes 
depending on subjective judgements with techniques such as willingness to pay (Drummond, 
et al. 2005; McCabe, 2009). 
Another economic evaluation approach that only deals with the initial (first) section of an 
economic evaluation is called cost analysis (Creese & Parker, 1994; Cunningham, 2000). The 
cost analysis approach is often used in disease-specific studies to assess the cost of providing 
healthcare.  On the other hand, the cost analysis approach does not assess outcomes, so it is 
considered as a partial economic analysis approach (Creese & Parker, 1994; Drummond, et 
al. 2005). When there are no data on interventions for a specific disease, researchers and 
policymakers can use cost analysis, particularly in areas that have not been explored before. 
A cost analysis of RHD in South Africa, for instance, may spur greater interest on the part of 
government in developing interventions, and the costs can also serve as inputs for future full 
economic evaluations. 
2.2 Cost Analysis in Healthcare   
When performing cost analysis for disease-specific cost of care, cost items can be valued using 
two approaches: ingredients (bottom-up) and step-down (Flessa, et al. 2011). Determining 
which approach to use for any chosen study is a key decision in costing which fundamentally 
affects the cost and the resources required to conduct the study (Cunnama, et al. 2016). In 
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simple terms, the ingredients costing approach is usually measured through multiplying 
resources used (input) by their prospective cost/price of the input (Rupert, et al. 2016). In 
order to estimate the unit costs, this approach uses detailed action and input utilisation data 
from records on detailed activities and observed resource usage from the level of the service 
provider (Batura, et al. 2014). The ingredients approach captures resource utilisation at 
individual or patient service level (Muennig & Khan, 2002; Mogyorosy & Smith, 2005). Its 
resource allocation is often based upon the authentic contribution of explicit resources, 
particularly indirect costs, such as administrative related costs, and others that support 
patient care and represent a significant proportion of the total cost of care (Chapko, et al. 
2009). It also uses the aggregate service level of resource utilisation data in order to classify 
the type of resources utilised by patients, as well as to estimate or calculate the cost of specific 
services rendered (Mogyorosy & Smith; Batura, et al. 2014). 
The step-down approach requires the analyst to take the overall expenditures of the 
inputs/ingredients at a central level (Conteh and Walker, 2004; Cunnama, et al. 2016). The 
allocation of costs in step-down costing are dealt with by using methods based on the 
allocation factors in order to establish unit cost of the service provider (Muennig & Khan, 
2002; Flessa, et al. 2011). 
Various studies comparing the ingredients costing approach and the step-down approach 
suggest that the ingredients approach is likely to be more precise because it captures 
resources more comprehensively and can be more accurate when compared to the step-
down approach (Hendriks, et al. 2014; Cunnama, et al. 2016). This is because the ingredients 
approach in principle is reliable and flexible, containing evenly detailed comprehensive data 
while its counterpart could contain data which may differ depending on the area of study 
(Wordsworth, et al. 2005; Cunnama, et al. 2016). The ingredients costing approach simply 
requires data which can be easy to access, and it is more suitable for non-homogeneous 
(intensive care) services compared to the step-down costing approach that assumes equal 
distribution of resource utilisation between patients (Negrini, et al. 2004; Hendriks, et al. 
2014). In addition, the ingredients costing approach enjoys resource utilisation measurement 
method flexibility when recording data, unlike the step-down costing approach which is 
dependent only on financial accounts data, as illustrated in Table 2 (Wordsworth, 2005).  
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Table 2: Measurement approaches (adapted from Mogyorosy & Smith (2005) and modified)  
                       
                                         
                 Costing approach in Relation to time 
Retrospective Prospective 
Data 
recording 
approach 
Ingredient
s costing 
Uses medical records, cost 
accounting, billing, surveys 
as well as  questionnaires  
Uses medical records, cost 
accounting, billing, surveys as 
well as  questionnaires  
Step-down 
costing 
Uses hospital information 
system (including 
accounting, accounts, 
vehicle register, etc.) 
In practice, it is not possible to 
obtain data easily. Unless 
assumptions are drawn on 
previously available data. 
As indicated in Table 2, because the step-down approach depends on financial accounts and 
other databases, it is retrospective in practice, while a bottom-up approach can be either 
retrospective or prospective. Prospective data collection can be more flexible and tailored 
towards the objectives of the study, but time consuming, expensive to commence, and it is 
specific to settings (Merx, et al. 2003; Simoens, 2009). The reason behind the downside of the 
ingredients costing approach could possibly be that it assesses cost of individual services 
within complex integrated healthcare systems, and that may account for its more limited 
acceptance (Chapko. et al. 2009; Cunnama, et al. 2016).  
On the other hand, the step-down costing can be less costly and faster compared to the 
ingredients costing approach (Mogyorosy & Smith, 2005; Cunnama, et al. 2016).  This is based 
on the fact that the step-down costing captures the total cost in a central/departmental level, 
and then dividing the total cost of the cost centres with the number of patients receiving 
treatment or the number of inpatient days (Waters & Hussey, 2004; Negrini, 2004; Chapko, 
et al. 2009). As a result, the step-down costing cannot be used to measure minimal alterations 
in resource consumption, for instance, inside hospitals, because the step-down costing 
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cannot differentiate between individual patient consumptions (Elliott & Payne, 2005; Simoes, 
2009). In turn, several studies where costing involved complex hospital services and partly 
where it lacks detailed available data regarding resource utilisation, the step-down costing 
approach could be the only feasible option (Adam, Evans & Murray, 2003). However, one of 
weaknesses of step-down costing is its being less accurate, and hence it captures less detailed 
retrospective data, as well as resource allocation that can be more or less subjective 
(Mogyorosy & Smith, 2005; Cunnama, et al. 2016). Furthermore, the aforementioned could 
be worsened by the fact that this approach may or may not contain the correct detailed 
information regarding the quantity of services rendered, nor the relative resources consumed 
for specific product/service in a reliable and sufficient manner (Muennig, 2002; Elliott & 
Payne, 2005). Therefore, a step-down approach could overestimate a unit cost of a service if 
patients acquire more services than an anticipated quantity or it could underestimate if fewer 
services are rendered than reported (Mogyorosy & Smith, 2005; Cunnama, et al. 2016).  
In addition, a study by Wordsworth, et al. (2005) that compared both step-down and 
ingredients costing approaches using two different diseases in France, Greece and Hungary 
established that the estimated costs and the actual cost differences depend on the costing 
method used. Other authors agreed with these findings, further stipulating that the 
ingredients costing approach is the most cost effective driver, as it is the only approach which 
clears up the real causes of cost differentials (Mogyorosy & Smith, 2005; Chapko, et al. 2009; 
Cunnama, et al. 2016), in addition to indicating the more practical weakness of the step-down 
costing side compared to its ingredient costing counterpart. However, the ultimate and 
practical accuracy of costing to estimate health systems costs/expenditures can best be 
common by comparing it to costing gold standard rules (Drummond 2005; Chapko, et al. 
2009). Unfortunately, gold standard rules for costing approaches do not exist as a result of 
controversies that would emerge as to whether ingredients, step-down, or utilisation of the 
mixed approach yields the best projection of ‘true costs’ (Mogyorosy & Smith, 2005; Mercier 
& Naro, 2014). In the absence of gold standard rules, researchers have different practical 
views about ingredients and step-down costing approaches (Chapko, et al. 2009; Cunnama et 
al., 2016). Further detailed explanation regarding the practical differences to some extent of 
researcher’s agreement regarding the two approaches is illustrated in Table 3.   
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 Table 3: Major practical methodological differences between ingredients and step-down approach  
Aspects of methodological 
differences 
Ingredients approach Step-down approach 
 Cost allocation Cost allocation, and shared 
cost distribution often more 
standardised i.e., greater 
consistency in between 
study/costing centres/sites 
Cost allocation of overhead 
costs often depends on the 
existing cost bookkeeping 
system as well as the 
distribution of shared costs. 
This could be unclear, not 
transparent and eventually 
differ by centres/sites 
Separation between unit 
price and resource 
Utilisation 
It permits separate recording 
as well as reporting of prices 
and resources. Prevailing 
higher transparency   
Not constantly possible to 
separate. more difficult in 
hospital related studies 
Data availability and 
reliability (unit prices and 
resource utilisation) 
Easy to attain well detailed 
data/information in standard 
format from any study 
sites/centres. It requires 
dedicated personnel since it 
requires intense time 
Difficult to attain detailed 
and well-structured 
data/information. It is even 
more difficult in LMICs, 
where cost bookkeeping is 
unsophisticated 
Data extensiveness Possible to be consistently 
detailed in different sites 
It differs depending on 
sites/settings   
Detection of treatment of 
disease policies, 
patterns/resource 
utilisation 
Possible to detect/identify the 
differences 
Challenging to identify. Not 
possible at times 
One of the few studies that compared and contrasted methodological aspects described the 
step-down approach as an approach that smooths out cost variances “over time and in 
between patients” because it applies similar weights to identical products/services regardless 
of individual/patient, time or setting (Chapko, et al. 2009). On the other hand, the ingredients 
approach was  described as an approach that puts emphasis on time and individual/patient 
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differences because it constructs costs from resource utilisation which can fluctuate ‘over 
time and in between patients’ (Conteh and Walker, 2004; Flessa, et al. 2011).  
Further studies that compared costing approaches using the national data in the United States 
of America highlighted that the strength of the ingredients approach was better able to 
capture site-level differences, whereas the step-down approach was better able to capture 
national long-run average costs (Chapko, et al. 2009; Flessa, et al. 2011). Currently, available 
costing literature also agrees with the fact that both approaches provide deviating cost 
estimates (Cunnama, et al. 2016). Studies focusing on questions and implications, such as 
when and under what conditions are these approaches complementary, and when and for 
what commitments should either perspective approach be used, are  vital to conceptualise 
the reasoning behind the existence of the differences between the approaches (Flessa, et al. 
2011). Thus, acknowledging these differences can assist researchers; however, it requires 
them to be explicit about their intended use of prospective approaches and potential 
measurement errors of their estimates that could arise as a result of single cost data source 
(Hendriks, et al. 2014).   
In practice, disease-specific studies have been utilising the mixed approach in their 
methodologies, somewhat driven by low availability of unit prices, detailed input and 
resource utilisation data (Drummond 2005; Chapko, et al. 2009). Several published studies, 
including Britain’s National Health Service (NHS) costing guidelines, the Veterans Affairs (VA) 
consensus guidelines in the USA, as well as a study of incremental cost of new technologies 
in South Africa, have applied the mixed costing approach (Swindle, et al. 1999; Mogyorosy & 
Smith, 2005; Cunnama, et al. 2016). The main advantage of implementing a mixed approach 
could be avoiding some of the weaknesses of both the step-down and ingredients costing 
approaches (Shepard, et al. 2000; Hendriks, et al., 2014; Cunnama, et al. 2016). This is because 
using a mixed approach can be cheaper than an individual ingredients approach, and it can 
be more accurate than employing merely a step-down approach, hence it reflects in variations 
of resource utilisations as required by several costing studies (Chapko, 2009; Hendriks, et al. 
2014).  
The importance of implementing a mixed costing approach allows researchers to prioritise 
cost estimation in relation to their study objectives, and determine where or on what to base 
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the direct cost estimation on (i.e. ingredients approach), and when to use the financial 
accounts based databases (i.e. step-down approach) (Mogyorosy & Smith, 2005; Hendriks, et 
al. 2014). This approach further assists cost of illness, cost analysis, and cost-effectiveness 
studies to cope with issues arising from missing data and/or gathering information/ collecting 
data which was not conventionally collected (Mogyorosy & Smith, 2005; Sarowar, et al. 2010), 
indicating that the mixed approach is routinely applied in cost studies to obtain estimates 
such as incremental costs that are used in cost analysis during economic evaluations. For 
instance, the study by Hendricks, et al. (2014) suggested that the staff costs be estimated 
using ingredients costing, while the building space and vehicles may be assessed using the 
step-down methodology. Recent literature that advocates for the usage of a mixed approach 
also calls for researchers to be clear about their objective when evaluating, mixing or 
assuming costing for different resource usages (Hendricks, et al. 2014; Cunnama, et al. 2016).  
2.3 Evaluation of Costs 
Cost evaluation depends on who utilises the resources and who incurs the cost. Cost solely 
borne by patients and households is called cost from a patient perspective (Weinstein, et al. 
(1996), while the provider perspective costs include solely of those costs that healthcare 
providers incur in a form of intervention (Creese & Parker, 1994). On the other hand, a 
societal perspective comprises both provider and patient cost perspectives, and it is the most 
comprehensive perspective of economic evaluations because it takes into consideration 
health benefits and profitability of any given intervention (Jonsson, 2009).  Costs of an 
intervention borne from the provider’s perspective in healthcare scenarios include cost 
estimations of medications, overheads and laboratory tests, but cost incurred by patients or 
households are not included (Creese & Parker, 1994). Such cost evaluations are vital when 
determining the practicality of piloting expansion and/or a change of interventions or even 
scaling up the existing one (Hongoro, 2017).  
Costs are made up of two different components, namely amount/quantity of resources 
utilised and their respective unit prices (Drummond, et al. 2005). Various elements of cost 
analysis are separately evaluated when estimating costs incurred.  Financial costs refer to the 
actual monetary expenditure on inputs utilised in order to provide goods or services, while 
the economic costs refer to the best alternative forgone or the opportunity cost of the 
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resources utilised (Conteh & Walker, 2004). Evaluating the opportunity cost of resources aid 
to account for the worth of resources which are donated and/or voluntarily provided. 
According to Drummond, et al. (2005), financial and economic costs are further categorised 
into capital or recurrent, depending on their estimated life years and value. Resources that 
are primarily a creation of fixed assets with a usable time frame of more than a year and value 
of greater than US$100 (i.e. buildings, furniture, vehicles) are capital costs (Hansen, et al. 
2010). Recurrent costs refer mainly to resources which are regularly purchased, and their 
estimated life expectancy is less than a year (i.e. salaries of personnel, electricity, 
medications) (Creese & Parker, 1994, Hansen, et al. 2010).  
The building costs are usually estimated by using square metre of spaces utilised and 
multiplied by the replacement value of buildings per square metre. The estimated financial 
costs of capital items are depreciated using a straight-line rate, while the economic costs are 
annualised using a discount factor of 3%, as advised by the World Health Organization (WHO) 
(Drummond, et al. 2005). The advised factor allows for depreciation and it accommodates the 
opportunity cost of purchasing the capital items (Hansen, et al. 2010). The estimated lifetime 
of 30 years for buildings and 10 years for equipment and furniture are used in costing 
research. Overhead costs for both outpatient and inpatient care are often estimated using 
patient day equivalent (PDE) (Clearly, 2007). The PDE is estimated as:  
PDEoutpatients = (annual inpatient days) 
1
𝑤𝑒𝑖𝑔ℎ𝑡𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟
) + (annual outpatient visits) 
PDEinpatients = (annual inpatient days) + (annual outpatient visits  weighting factor) 
The weighting factor is the average ratio of overhead costs per outpatient visit to the cost per 
inpatient day, whereas the standard assumption in South Africa is that an outpatient visits 
costs one-third (
1
3
= 0.33) of an inpatient day cost (Clearly, 2007). The outpatient visits and 
inpatient days PDE will be estimated as; 
PDEoutpatients = (annual inpatient days  3) + (annual outpatient visits) 
PDEinpatients = (annual inpatient days) + (annual outpatient visits  0.33) 
Therefore, overhead costs of outpatient visit and inpatient day will be calculated as: 
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Overhead cost per outpatient visit = 
annual overhead expenditure
PDEoutpatients
 
Overhead cost per inpatient day = 
annual overhead expenditure
PDEinpatients
 
2.4 Discounting and Annuitisation   
Discounting is used to determine the present value of resources that is to be received in the 
future (Walker & Kumaranayake, 2002). Researchers often utilise it to adjust future outcomes 
of resources and their respective present-time value. This is important given the fact that the 
values of resources vary depending on when they are being used and yield benefits. 
Drummond, et al. (2005) stated that individuals choose to obtain benefits in the present and 
pay in the future. Thus, to account for this time preference, discounting is utilised to adjust 
for future costs and future outcomes. Usually, such resources fall into a capital cost category 
and are purchased once off (Hansen, et al. 2010). A discount rate of 3% & 5% are often used 
by researchers to ensure the robustness of the outcomes (Vassal, et al. 2017).  On the other 
hand, annuitisation is used by researchers to allocate the economic cost of capital items for a 
given year. It is performed by taking into account depreciation and the interest from the 
investment foregone in order to purchase these items (Walker & Kumaranayake, 2002). The 
lifetime of the capital items vary accordingly, mostly 30 years is used for buildings, 10 years 
for furniture, and 5 years for vehicles (Creese & Parker, 1994). However, discounting and 
annuitisation rates differ depending on the settings and the assumptions utilised particularly 
in disease-specific programs and preventions. And there are available costing tools with a 
detailed list of ingredients and some collection of overhead costs at the service level to guide 
researchers when estimating disease-specific costs in LMICs (UNAIDS, 2011; WHO, 2016).  
2.5 Review of Methods Used to Estimate Cost of Disease Specific Care: Health 
Systems Perspective  
In general, inpatient costs are neglected for non-communicable disease (NCDs), 
predominantly CVDs. Estimating the costs for CVDs include economic measures to assess the 
impact of disease treatment on healthcare costs (Radensky, et al. 2001; Saxena, et al. 2006; 
Riley, et al., 2016). However, most of the CVDs literature to date has focused on outpatient 
primary care/prevention costs as a rule of thumb to estimate cost estimations (Adam & Evans, 
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2006; Toulany, et al. 2015), whereas the ratio of inpatient cost of care to outpatient cost of 
care vary according to hospital size and occupancy rate (i.e. rules of thumb do not hold 
accurate cost estimation) (Kalisvaart & Hergenroeder, 2007; Toulany, et al. 2015). Few 
systems cover resource usage in general, while a broad system focus on major drivers of total 
costs, such as inpatient hospitalisation care (Adam & Evans, 2006; Hansen, et al. 2017). 
Studies, such as Radensky, et al. (2001) and Hansen, et al. (2017) imposed different 
approaches to categorise costs in order to estimate resource utilisation of cardiovascular 
events. The former derived costs from hospital bills, while the latter obtained the estimation 
of provider costs from the payer allowances, as well as various cost reports and financial 
analyses. This makes comparison between results difficult and incomparable among different 
trials and analyses (Radensky, et al. 2001; Hansen, et al. 2017).  
On the other hand, several studies highlighted that the length of hospital stay (inpatient care) 
is the largest portion and a determinant of total cost in healthcare costing (Macario, et al. 
1995; Radensky, et al. 2001; Saxena, et al. 2006; Toulany, et al. 2015). A study that 
investigated hospital costs of surgical procedures estimated total cost through dividing it into 
operating departments, such as operating room, ward, surgery admission unit, laboratory, 
pharmacy and miscellaneous (Macario, et al. 1995). The authors further subdivided the 
departments to accommodate unit costs of all events, using patient-specific data. As such, 
operating costs comprised the equipment, labour and supplies utilised once the patient had 
been admitted for inpatient care, while miscellaneous included the ambulatory services, 
therapy and dietary services (Macario, et al. 1995).  
Radensky, et al. (2001) also assessed costing methods for inpatient care costs of major CVD 
events. The study established that average inpatient hospitalisation costs can be calculated 
using patient level data, given national estimates. For instance, the estimation of admission 
costs for an individual event was recommended to be calculated from the average hospital 
costs of all charges for patients, followed by converting the charges per admission to estimate 
the costs per admission and utilising the national median cost-to-charge ratio. While the cost 
of physician(s) was suggested to be included only for patients who went through surgery, the 
total cost-to-charge should be obtained from the sum of individual cost-to-charge ratio of 
operating and capital costs. The findings proved that total direct cost of hospital stay and 
discharges to institutions in stroke patients were determined by medical complications 
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(Radensky, et al. 2001; Saxena, et al. 2006). In addition, empirical literature indicates that low-
and-middle income countries face additional alarming issues, such as health systems being 
generally ill-equipped to manage chronic disease, as well as to measure the cost of 
hospitalisation care (Brouwer, et al. 2015; Hansen, et al. 2017).  
3. Review of Studies on the Cost of RHD to Health Systems 
3.1 Search Strategy  
A published papers search was conducted according to the databases content with the main 
focus of containing economics field literature. The search included the following databases: 
PubMed (NCBI), Scopus, EBscoHost (CINAHAL), EBscoHost (EconLit), EBscoHost (Africa wide 
information), and Central Cochrane. Search terms specifically adapted to each database using 
1) terms related to ARF/RHD and some risk conditions; 2) terms related to health systems and 
healthcare provider; and 3) terms representing cost. The full systematic search report and the 
search strategy process can be found in Appendix D. Out of 481 studies, 29 studies met the 
inclusion criteria of studies of the cost of RHD from the health system perspective, given the 
restricted disease condition of interest to ARF and RHD.  
The number of published articles for ARF/RHD in LMICs is unsurprisingly rare. Most of the 
studies on the burden/cost/cost-effectiveness of ARF/RHD are conducted in upper middle 
and high income countries, with very little studies attempted in low-income countries. 
Regardless of whether the studies are cost related or not, the sample studies are mainly from 
Asia and the Unites States, dominated by studies from India. Figure 2 provides the year and 
number of articles published from 1999 to date. The year 2013 saw the highest number of 
articles discussing ARF/RHD burden-related articles which was not surprising, given the 
increase of research on cardiovascular studies in general, as confirmed by Elizabeth, et al. 
2015 study. 
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Figure 2: Number of published articles related to burden of ARF/RHD from 1997 up to date  
 
3.2 Cost Estimation and Management of ARF/RHD Burden  
The search review identified 7 studies that focused on the treatment and management of 
RHD and post-RHD conditions. The cost of pre- and post-RHD complications also includes 
treatment of sore throat, ischemic heart disease, stroke, heart failure, among others. 
Treatment or the care of RHD typically consists of screening, diagnostic procedures, surgical, 
and other advanced treatments, and post-surgical and long-term outpatient care (i.e. 
medications and check-ups). The highest inpatient costs were associated with long hospital 
stay days that are related to more severe conditions of RHD. The costs ranged from $49 for 
part of inpatient treatment to $128,000 for inpatient care, including surgery and hospital stay 
per-patient. The mean inpatient cost of ARF/RHD varied widely, depending on the 
geographical settings, the actual resources utilised and the mean length of hospital stay. 
However, most of these articles provided estimated cost, treating ARF/RHD without 
distinguishing neither the severity of the disease nor do they clearly establish a breakdown of 
outpatient and inpatient costs.   
It was also evidenced that RHD is a declining disease in developed world that affects the 
elderly as hidden during its early stages, and that it is regularly associated with supplementary 
chronic diseases (Marijon, et al. 2012). As a result, developed countries face more per-patient 
cost of RHD, given that they have higher prices and greater utilisation of advanced medical 
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care than their developing counterparts (Marijon, et al. 2012). The difference in prices and 
utilisation highlights as the cost of RHD treatment varies from region to region. For example, 
per-patient cost of care in the United States of America in 2002 was about $6000 (Ehrlich, et 
al. 2002), while per-patient cost in China in 2012 was about $4700 (Wang, et al. 2015). A study 
from Havana, Cuba also indicated that the cost of severe RHD care in the 1990s was about 
$6300 (Watkins, et al. 2015), while the cost burden per-patient in South Africa for merely 
inpatient care in 2010 was $2900 (about R39, 000) (Irlam, et al. 2013).  
A hospital-based study of 453 RHD attributed ischemic stroke patients by Hashmi, et al. (2013) 
at one of Pakistan’s largest tertiary care hospitals found that the average cost of care per-
patient was 70 714 rupees (US$1179). The average cost of care per-patient was confirmed to 
be much higher than the per capita income of US$672 in Pakistan (Hashmi, et al. 2013). 
Another study from New Zealand further highlighted that hospital admissions and related 
yearly costs to the government were more expensive in the age group 5 to 14 years (Richard, 
et al. 2012). From the costs incurred, non-surgical expenses were the highest expenses that 
accounted for well over half of the total provider cost (Richard, et al. 2012). However, hospital 
admissions for RHD are more common among Brazilian patients in the age group 20 to 60 
years.  (Guilherme, et al. 2012). Brazil has also witnessed a low frequency of RHD patients 
towards hospital admissions because the recent disease burden belonged to a younger age 
group (Guilherme, et al. 2012). With a mean follow-up time of 3.9 years (age range 1–10 
years), patients had a total of 1657 medical consultations, 22 hospital admissions and 4 
admissions to an intensive care unit (Guilherme, et al. 2012). 
At the same time, the economic impact of RHD is felt more by LMICs health systems because 
these countries encounter much higher numbers of RHD cases, with limited resources 
(Mayosi, et al. 2006; Koech & Ngeno, 2014). In African countries, the direct medical cost of 
treating one patient with RHD in six years was estimated to be US$17375 in 1987, increasing 
to US$31661 with surgical procedures (Ekra & Bertrand, 1992; Olubodun, 1994). A study that 
estimated the cost of treating patients with RHD in Nigeria confirmed the equivalence of the 
burden from treating one patient to the cost of preventing 5.4 cases (JaiyesimI, 1982). The 
main burden is the costs of outside referrals that are often required during the course of 
treatment, adding to the challenges that the health systems of developing countries are 
confronted with.  
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As a result, the majority of children and adults in Africa who live with RHD have lost 
opportunities for prevention because of limited resource allocations towards preventive 
interventions, such as treatment of sore throat (Cilliers, 2015). This concurs with the findings 
by Terreri, et al. (2001). The consequence of this limited resources or misallocation to patients 
and health systems is the high cost of irreversible heart valve damage that can only be 
alleviated by surgery, if it is available at all (Gunter, Asmera & Parry, 2006; Watkins, et al. 
2016).  
Another factor impacting the cost estimation of ARF/RHD and causing variation in costs 
reported across studies was differences in methodology utilised.  The absence of standard 
reporting across all the studies, through mainly a lack of clear descriptions of the cost 
ingredients, was a notable failure. Studies lack clear and common categories for input or 
motion cost categories while disaggregating costs, as shown in table 4. Furthermore, it was 
also unclear how the costs were disaggregated when motions comprised personnel in the 
costs estimation. For instance, several studies provided cost estimation of echocardiographic 
screening, dispensing penicillin and diagnostic activities including surgery but the personnel 
costs were not stated clearly. Significantly, studies did not describe what resources compared 
in surgery or surgical procedures, regardless of surgery being a common category of the RHD 
burden that demands intense resource usage. In general, ARF/RHD studies to date have 
focused on the clinical portion of the burden but not the cost analysis and the breakdown of 
the ingredient costs.  
3.3 Interpretation and Implications of Reviewed Studies for This Thesis 
It is evident from the current literature that a small body of information exists regarding cost 
analysis of ARF/RHD in general. This is despite the presence of significant evidence from a 
wide range of studies on economic evaluation in CVDs, while those that particularly address 
RHD-related diagnosis are rare globally. In the case of South Africa, no study clearly stipulates 
the cost of ARF/RHD from a health systems perspective. This gap in information needs 
attention witnessing. It has been noted that in Cuba the role of economics and economic 
evaluations are vital in ARF/RHD, thus, the country evidenced dramatically reduced morbidity 
and premature mortality in children and young adults while reduced 90% of the cost (Watkins, 
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et al., 2015). It is most important for policy decision making to be dependent on such robust 
evidence.  
Having robust evidence regarding RHD care would assist countries such as South Africa where 
replacing affected heart valves is expensive but literature addressing estimated amount is 
rare and unclear. In addition to that, individuals who have undergone surgery also face 
additional challenges that require more heart operations, making them more susceptible to 
complex, lifelong heart problems and their attendant costs (Marijon, et al. 2012). Such 
challenges have potentially been forcing the public health facilities to limit the number of 
valve surgeries that can be performed. As a consequence, many South Africans die while 
awaiting valve surgery (Zilla, 2014). Cuba is a model country that has increased the coverage 
of treating sore throat and introduced ARF interventions and thus seeing RHD expenditure on 
heart surgery falling by about 90% within a decade following a comprehensive RHD 
prevention program (Watkins, et al. 2015).  
Table 4 presents the summarised unit and/or total costs reported of different countries. The 
currencies of different nations were first converted to the respective country’s local currency 
using the average exchange rate in the year of study if the United States dollar (US$) or some 
other currency is used. Costs were then inflated from the year cost/value presented in the 
articles to the cost/value of using the respective country’s average inflation rate (ratio of CPI 
in 2017 to CPI in base year), and finally converted to 2017 South African Rand (R) to the United 
States dollar (US$) using the 2017 exchange rate.  
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Table 4: Health systems cost data of ARF/RHD care/treatment (US$ 2017) 
Study author 
and year 
Nation Study population (n) 
and group (age) 
Sub-
condition/prevention/ 
care/ 
treatment type 
Costing 
methods  
used 
Costing 
Unit 
Cost in ZAR 2017) 
(Watkins, et al. 
2015) 
Cuba n=273933 (age 5 to 24) Cost of severe RHD 
hospitalisation  
Decision tree 
model  
Per 
episode 
US$6606.86 
(Irlam, et al. 
2013) 
 
South 
Africa 
 
n=97 (age 3- 15) 
Daily penicillin + 1 set of 
lab tests/ECG/echo/CXR 
Markov model 
to assess the 
cost-
effectiveness of 
care  
Per 
patient 
US$3107.12 
(Irlam ,et al. 
(2013) 
 
 
South 
Africa 
 
n=97 (age 3-15) 
Inpatient treatment of 
RHD (7 days admissions) 
Markov model 
to assess the 
cost-
effectiveness of 
care   
Per 
patient 
US$16776.85 
(Irlam, et al. 
2013) 
 
 
South 
Africa 
 
RHD patients 
Lowest cost of Penicillin 
for acute sore throat 
Unclear Per 
Patient 
US$11.75 
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(Milne, et al. 
2012) 
 
 
New 
Zealand 
 
n=7404 (age - 14 and age 
45- 79)  
Annual admissions cost for 
diagnosis of ARF or RHD  
Ingredients 
approach 
Per year 
n=7404 
US$13,528,122.37  
(Revees, et al. 
2010) 
 
 
 
Fiji 
 
n=362 (age 5- 15) 
Echocardiographic 
screening for RHD in 
schools 
 
Unclear  
Per-
patient 
detected 
US$42.03 
(Soudasanane, et 
al. 
2007) 
 
India  
n=178069 (age 5-15) 
surgery at average of per 
procedure  
Ingredients 
approach 
Per 
patient 
US$1003.24 
(Jacqueline, 
2002) 
 
 
USA 
 
n=173 (age 5 - 17) 
Treating ARF with 
antibiotic  per episode 
Unclear Per 
patient 
US$54.39 
(Terreri et al. 
2001) 
 
Brazil 
n=100 (age less than 18) Direct cost to public health 
care provider per episode 
Ingredients 
approach 
Per 
patient 
US$483.88 
(Michaud et al. 
1999) 
USA n=2000 (3 months to 20 
years) 
Cost of ARF admission and 
subsequent care per 
episode 
 
Unclear 
Per-
patient 
per year   
US$14722.75 
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Most of the studies on the cost of RHD were conducted in middle income and high income 
countries, with alarming absence of investigative research in highly affected low income 
countries. Yet, the available evidence indicates that RHD management is expensive, being 
both a health factor as well as a long term economic burden. In Table 4, the cost components 
of different RHD related care shows variation in cost depending on the region and country. 
The USA seems to have the highest cost of ARF admission and subsequent care per episode 
(US$14722.75) compared to the US$6606.86 cost per episode for severe RHD conditions in 
South Africa. The drivers of cost of RHD care costs in all countries regardless of the unit cost 
of the care are hospitalisation and surgery in severe cases, while follow up outpatient costs 
are driven by a cost of RHD medications.  
Therefore, it is shocking to witness the absence of economic evaluations (cost analysis) of the 
disease in lower economic regions to guide governments and policy makers to overcome 
prevalent barriers to ARF/RHD and its care. Some of the barriers are related to community 
awareness and the primary healthcare level treatment options that are available, affordable 
and acceptable (Zuhlke, et al, 2015; Moloi, et al. 2016). Given these barriers and budgetary 
constraints, it is crucial for public health systems to address these constraints in a 
contextualised and economically efficient manner (Longenecker, et al. 2014) 
4. Conclusion  
This literature review stressed about partial economic evaluation studies called cost analysis 
in ARF/RHD care and studies that reviewed the cost of illness. Evidence shows that ARF/RHD 
treatment/care and control/prevention costs in LMICs are highly inadequate, mainly in low-
income countries. The research shows that global attention regarding the costs of this 
neglected disease alongside the efforts to scale up treatment and preventions in these 
settings is limited. Firstly, global attention should be focused on using standard methods of 
care (i.e. clinical protocol) to create cost information of ARF/RHD treatment and prevention 
especially to estimate key cost drivers across settings. Secondly, there is a major need to 
estimate actual resource use and costs in the provision of care, as such information can be 
used to improve efficiency and budgeting over time, particularly in high ARF/RHD prevalent 
countries (i.e. low-income). In addition, disease-specific research, such as ARF/RHD cost 
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estimation, lacks cost input disaggregation mainly the long-term burdens given most 
individuals practice disease sequelae over time, even after surgery (Marion, et al. 2012). 
The African continent where 10% of the world’s population resides hosts 50% of the RHD 
victims who lack an understanding of the needed resources to tackle the ARF/RHD endemic 
(Ntusi & Mayosi, 2009; Koech & Ngeno, 2014). The literature indicates that to date there has 
been no full cost analysis (from outpatient to surgery) performed in depth to evaluate the 
cost of RHD care in South Africa. To this researcher’s knowledge, there is no comparative 
study of cost and cost-effectiveness of different types of RHD preventions (feasibility of 
primary prevention vis-à-vis secondary and tertiary preventions) for the management of the 
disease in South Africa. This study has revealed the existence of only two studies that assessed 
the cost of penicillin and inpatient days cost in the South African context, yet none in the 
context of other nations. While the gap is substantial and will continue to increase in the 
absence of concentrated prevention efforts, which could contain costs by reducing future 
spending on ARF/RHD. The need exists for future cross-country studies on countries such as 
Ethiopia, Mozambique and Uganda. Ongoing efforts to comprehend the cost of providing 
ARF/RHD care in these countries will be critical towards attaining universal health coverage 
(UHC) and improving the overall population health on the continent. 
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The Health System Cost of 
Rheumatic Heart Disease in 
the Western Cape Province 
of South Africa. 
Abstract 
Background 
Rheumatic Heart Disease (RHD) is a disease 
of poverty that is neglected in developing 
countries, including South Africa. Lack of 
adequate evidence regarding the cost of 
RHD has hindered national and 
international actions to prevent RHD 
related deaths. The objective of this study 
was to estimate the cost of RHD-related 
health services in a tertiary hospital in the 
Western Cape, South Africa. 
Methods 
A mixture of ingredients and step-down 
costing approaches were used to estimate 
the cost of RHD care from health system 
perspective. Health system perspective 
costing is often used by researchers when 
there is interest on finding the costs borne 
by the healthcare provider only (17). All 
costs were estimated in 2017 (base year) 
South African Rand (ZAR) and 3% discount 
rate in order to allow depreciation and 
opportunity cost of purchased capital 
items (13). Data on service utilization rates 
were collected using a randomly selected 
sample of 100 patient medical records 
from the Global Rheumatic Heart Disease 
Registry (REMEDY) study, a registry of 
individuals living with RHD. Patient-level 
clinical data, including, prices and 
quantities of medications and laboratory 
tests consumed, were collected from 
Groote Schuur Hospital (GSH), the main 
site of cardiac care for these individuals. 
Step-down costing was used to estimate 
provider time costs and all other facility 
costs such as overheads. REMEDY and GSH 
data were aggregated to estimate the total 
annual costs of RHD care at GSH and the 
average annual per-patient cost among 
REMEDY participants. One-way univariate 
sensitivity analysis was conducted to deal 
with uncertainty.  
Results 
The total cost of RHD care at GSH was 
estimated at $2, 238, 294 (ZAR27 million) 
in 2017, with surgery costs accounting for 
65% of total costs. Per-patient average 
annual costs, which included outpatient 
care, cardiac medical and intensive care 
unit (ICU) care, cardiac catheterisation 
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laboratory (Cath lab) procedures, and 
heart valve surgery, was estimated at $4, 
311 (ZAR52, 000) per-patient annually. The 
cost of medications in outpatient unit care, 
and consumables related to cardiac 
catheterisation and heart valve surgery 
were the main cost drivers.  
Conclusion 
RHD care consumes a significant level of 
tertiary hospital resources in South Africa, 
with annual per-patient costs much higher 
than many other non-communicable and 
infectious diseases. This analysis supports 
the scaling up of primary and secondary 
prevention programmes at primary health 
centres in order to reduce the future 
burden on tertiary services. The study may 
also inform resource allocation efforts 
related to RHD at tertiary centres and 
provide cost estimates for future studies of 
intervention cost-effectiveness.  
Keywords 
Unit cost, cost analysis, health systems, 
provider cost, rheumatic fever, rheumatic 
heart disease, surgery, tertiary care, 
cardiology 
1. Background 
Rheumatic heart disease (RHD) is the most 
common acquired cardiovascular disease 
among children and adolescents in 
developing countries. (1, 3). RHD is a 
chronic inflammatory disease of the heart 
valves that result from recurrent episodes 
of acute rheumatic fever (ARF).  Heart 
valve disease often leads to heart failure, 
stroke, and premature death including 
among children and young adults (23). 
Recent studies have estimated about 33 
million prevalent cases and 320,000 deaths 
from RHD globally in the year 2015 (3, 10). 
African countries have some of the highest 
rates of RHD in the world (23). Previous 
studies in higher-income areas of the 
world have documented that the cost of 
RHD is high because most affected 
individuals experience a lifetime of repeat 
hospital admissions and expensive surgical 
care; the physical and psychological impact 
on patients and households is also 
significant (2). The condition results in high 
levels of resource use in ill-equipped and 
under-financed public health facilities in 
poor countries (3, 4). Even though surgery 
can save or prolong life, access remains 
low in many countries due to lack of early 
diagnosis and prompt referral – as well as 
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shortages in surgical services themselves 
(37).  
Lack of information on the cost of RHD is a 
barrier to equitable allocation of resources 
to prevent and treat the condition and 
assess new RHD technologies and 
interventions through comparative cost-
effectiveness analyses (15, 16). A recent 
review found very few studies on the 
economics of RHD, and no studies of the 
cost of care in the African context (38). The 
objective of the present study is to 
estimate cost of care for RHD from the 
public health system (provider) 
perspective at a tertiary hospital in urban 
South Africa. This study looks at outpatient 
costs and inpatient costs at three different 
levels of care. The study focusses on two 
topics: (a) estimating the total costs 
incurred at Groote Schuur Hospital (GSH) 
in 2017 because of RHD, (b) estimating the 
per-patient annual cost of care among a 
representative sample of individuals 
requiring tertiary care. 
2. Materials and Methods 
2.1 Ethics Approval  
Ethical approval was obtained from the 
University of the Cape of Human Research 
Ethics Committee (UCT_HREC Ref: 
436/2017) as well as the Western Cape 
Department of Health (WCDoH) prior to 
commencement of the study. During the 
medical records review, privacy of patients 
was maintained, and no identifying 
information such as patient participants’ 
names and identity numbers were 
collected.  
2.2 Study Setting and Population 
This cross-sectional cost analysis study was 
carried out in 2017 at GSH, which is a 
public tertiary level healthcare facility that 
serves patients of the Western Cape 
Province and beyond. A devoted cardiac 
clinic within GSH provides care for cardiac 
patients (including RHD, ischemic heart 
disease, heart failure, endocarditis, and 
more) on average for about 7400 patients 
annually. Inpatient wards also provide 
acute care services in a cardiac intensive 
care unit (ICU), cardiac catheterisation 
laboratory, and cardiac surgical theatre. In 
this study, cost data from GSH were 
complemented with more detailed data on 
patient utilisation of health services that 
were obtained from 100 participants in the 
REMEDY study, an international registry of 
RHD that includes several hundred cases at 
GSH (14).  
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2.3 RHD Pathway of Care 
The cardiac clinic (E17) in GSH is the oldest 
devoted outpatient clinical cardiology 
service in sub-Saharan Africa. Patients who 
get diagnosed with RHD in E17 come 
through different referral pathways such 
as emergency departments, primary care 
clinics, and other referral clinics within or 
outside GSH. Care in E17 is provided by 
senior registrars, consultants, and 
registered nurses, among others. RHD 
patients are identified through detailed 
investigation of blood, electrocardiogram 
and echocardiography tests. Stable 
individuals with RHD are seen on one of 
three weekdays during which dedicated 
clinic sessions are held.  
Patients with appointments for normal 
RHD follow-up care first collect their 
medical record folder from the 
receptionist then are seen by a nurse who 
performs routine screening activities and 
reviews the medical record. Depending on 
the appointment category (as indicated in 
the medical record evaluation) and the 
results from clinical measurements, 
patients are attended by a registered 
nurse, registrar, or consultant, or if there 
are severe or acute issues are referred to 
the emergency unit or admitted as 
inpatients at GSH. Patients with RHD visit 
GSH as infrequently as twice yearly if they 
are clinically stable. Routine appointments 
are given with a one month supply of 
medications and instructions to return in 
about 6-12 months unless complications 
arise. Follow-up appointments are planned 
to evaluate progression of disease and 
assess adherence to treatment. Annually, 
about 100 new patients are enrolled in the 
RHD clinics at GSH. During the REMEDY 
study (which recruited 448 participants 
from 2012 to 2014), staff members 
reviewed and selected new patient folders 
for further follow up for research purposes 
and separately documented usual 
standard of care (i.e., medications, 
appointments, contact details) in order to 
investigate the clinical epidemiology of the 
disease. The observational REMEDY study 
did not provide any care to RHD patients; 
however, they captured major adverse 
events and instances of defaulting on 
medications or other aspects of care. 
Notably, pharmacy (refill) visits are few 
and are much less resource- demanding 
compared to clinical follow-ups; often 
patients collect pre-packed and dispensed 
medications from a third-party provider. 
Hence this study did not estimate 
pharmacy visit costs outside GSH. 
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2.4 Approach 
2.4.1 Overall Approach  
A health systems (provider) perspective 
was adopted. Retrospective costing for 
patients with diagnosis of RHD was 
conducted using mix of the ingredients 
approach and step-down approach by 
aggregating costs at different levels of care 
(e.g., outpatient and various inpatient 
wards). The ingredients approach was 
generally used to estimate direct costs 
such as medications, while the latter was 
generally used to estimate indirect costs. 
All data were collected from January 2017 
to December 2017. Costs were calculated 
in South African Rand (ZAR) using 2017 as 
the base year. A standardised set of four 
data collection instruments was used: one 
for each of the major clinical units where 
RHD care is delivered at GSH. These clinical 
units are: outpatient clinic (E17), medical 
and ICU ward, cardiac cateterisation 
laboratory (C25), and surgical theatre 
(D21).  
2.4.1.1 Ingredients Costing  
This approach primarily used detailed 
medical records and observations to 
measure specific resources required for 
delivering RHD care. Utilisation patterns of 
resources such as, medications, laboratory 
tests, and diagnostics and consumables 
related to RHD care were collected. For 
example, the cost of medications were 
estimated according to the number of 
medications recorded as dispensed for 
each of the 100 REMEDY participants then 
multiplied by the cost per 
dosage/injection. Other approaches for 
determining ingredients used included 
semi-structured interviews of providers to 
establish resource use. REMEDY and other 
hospital medical records were reviewed to 
establish utilisation rates for specific 
services, and semi-formal interviews with 
clinical experts in RHD care were also 
conducted.  The cost share of cardiac 
medical and ICU care on RHD was 
calculated using the number of inpatient 
bed-days at GSH; i.e. by multiplying the 
number of admissions with the average 
length of stay. The average length of stay 
of individuals with RHD in the cardiac 
wards was 4.73 days per admission 
according to the most recent annual 
report.   
Price lists were obtained from the Western 
Cape Department of Health (WCDoH). As 
per treatment guidelines and the data 
obtained from medical records, direct 
medical costs were calculated using the 
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accounting identity; i.e., costs incurred are 
the product of prices and quantities of 
goods and services consumed. 
2.4.1.2 Step-down Costing 
Step-down costing approach is commonly 
used to estimate costs that are long-term 
but not directly related to the patient 
utilisation, including costs borne by 
support departments in health facilities 
(17). Capital costs (e.g., medical building, 
equipment and furniture) and recurrent 
indirect costs (e.g., overhead costs 
incurred by GSH, electricity, water, 
cleaning, security) of proving RHD care 
were costed using the step-down 
approach.  
Capital costs and their respective expected 
life years were obtained from the hospital 
procurement department. Original costs 
obtained were also inflated to ZAR 2017 
costs using the consumer price index. 
Specifically, equipment and furniture item 
costs were apportioned to RHD care 
according to the share of RHD patients 
using the items. Building costs were 
estimated using square meter of space 
used in RHD care. Costs were calculated by 
multiplying by the building replacement 
value per square meter $3, 206 (ZAR 
38,670), which was obtained from the 
building and engineering company-
approved tender estimate for GSH (22). 
Recurrent cost data were obtained from 
the finance department of GSH for the 
2016/2017 financial year. As 
recommended by the World Health 
Organization (WHO), capital items were 
discounted and annualized using a 
discount factor of 3%, reflecting the 
opportunity cost of purchasing the capital 
items (13). An estimated lifetime of 30 
years for buildings and 10 years for 
equipment and furniture were used (13, 
17). Sensitivity analyses were conducted 
using 0%, 5% and 10% discount rates with 
the upper range (10%) corresponding to 
the maximum discount rate used in cost-
effectiveness studies for South Africa to 
verify the robustness of the results (12, 13, 
20, 42).  
Costs were categorized into overheads and 
final service centres (17). The overhead 
costs include resources that cannot be 
directly associated to care, while the final 
service centres include resources used in 
care (13, 18). Overhead costs comprise 
cost of general support services 
departments that are important for the 
facility to operate (13, 17). These include 
utilities (i.e. electricity, water), non-clinical 
personnel (i.e. cleaning, security) as well as 
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stores that provide non-patient specific 
services (36). Overhead costs were 
estimated by assessing the overhead 
expenditures assuming that all patients 
utilise equal amount of overhead costs 
when they visit the healthcare facility 
during a given period of time (36). The 
calculation for overhead costs per visit was 
the annual overhead expenditure divided 
by annual number of patient visits. This 
approach was used for both outpatient 
and inpatient departments of GSH because 
a cost centre accounting system does not 
exist in the hospital. Overhead 
expenditures were allocated directly to 
outpatients and inpatients departments 
using an allocation factor based on the 
patient day equivalent (PDE) concept (17, 
36). PDE is estimated as:  
PDEoutpatients = (annual inpatient days) 
1
𝑤𝑒𝑖𝑔ℎ𝑡𝑖𝑛𝑔 𝑓𝑎𝑐𝑡𝑜𝑟
) + (annual outpatient 
visits) 
PDEinpatients = (annual inpatient days) + 
(annual outpatient visits  weighting 
factor) 
is the local practice at the University of 
Cape Town is to employ the (empirically-
based) rule of thumb that an outpatient 
visits costs one-third (1/3) of an inpatient 
day, and this is used as a weighing factor 
(36).  
Overhead costs per outpatient visit and 
inpatient day at GSH are thus expressed as: 
Overhead cost per outpatient visit = 
annual overhead expenditure
PDEoutpatients
 
Overhead cost per inpatient day = 
annual overhead expenditure
PDEinpatients
 
Costs of different centres within GSH that 
render services to the entire hospital (i.e., 
intermediate costs) were incorporated in 
overhead costing; these included the 
pharmacy and laboratory departments 
(18). These intermediate and overhead 
costs were later added to final cost 
department in gradual manner. Recurrent 
and capital costs were also allocated to the 
four clinical units (outpatient, medical and 
ICU ward, cardiac catheterisation lab, and 
surgical theatre) directly according to their 
actual resource utilization. For instance, 
estimates of square meters of space used 
directly for care were used to distribute 
the building costs to the four units. 
Incurred recurrent and capital costs were 
distributed according to clinical unit using 
allocation bases and resource usage. For 
instance, the number of individuals with 
RHD as a percentage of total number of 
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patients served in each clinical unit were 
used to calculate utilization factor, hence 
the share of costs allocated to RHD.  
There was no cost incurred by GSH for 
training nurses or other staff personnel 
specific to RHD, however, lectures were 
given by senior registrars to nursing staff 
every Tuesday; nurses also had an 
opportunity to participate in 
catheterisation procedures to teach them 
about post-procedure care.  
Finally, step-down cost estimates were 
added to the ingredients cost estimates to 
arrive at total costs. The total cost per 
admission was estimated by multiplying 
the average cost per inpatient day by the 
average length of stay. The annual cost of 
care per-patient at each of the four clinical 
units was calculated as the product of the 
unit cost (per encounter) times the annual 
utilisation rate. The overall annual cost of 
care per-patient was calculated as the sum 
of annual costs at each of the four clinical 
units. For comparison, the total cost of 
providing RHD care at GSH in 2017 was 
extracted from the spreadsheets as the 
aggregate costs at each of the four clinical 
units (i.e., the costs required to deliver care 
for all individuals with RHD, including but 
not limited to the 100 REMEDY 
participants). 
2.4.1.3 Personnel Costing 
Statistics regarding time allocation, and 
time spent by different personnel 
providing care or consulting patients were 
not available at GSH. Particularly how long 
a service takes to deliver, hence the 
proportion of each staff member’s salary 
allocated to RHD care. Additional 
information was obtained from key 
clinical/hospital experts and ward 
operational managers through non-formal 
interview and review of their weekly duty 
excel spreadsheets. Eight non-
participatory observations were 
conducted to understand patient 
management and staff time allocation and 
to identify and examine the costs involved. 
The limitation of this strategy is that 
responses could not be authenticated 
through time-motion studies hence it 
might over or underestimate the share of 
time spent on providing RHD related care.  
2.5 Data Analysis 
Study data was entered into Microsoft 
Excel for quality evaluation then later 
imported into STATA 14 (Statacorp, 2015). 
Descriptive statistics (means, proportions, 
etc.) were used to assess participants’ 
demographic characteristics.  
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2.5.1 Sensitivity Analysis  
In order to assess the impact that changes 
in assumptions or parameters would have 
on final cost estimates, one-way 
deterministic sensitivity analysis was 
performed. The following cost model 
inputs were varied: (a) discount rate of 0%, 
5% and 10% on capital costs (19, 20); and 
(b) utilisation rates of the four clinical units 
were varied from base values to lower and 
upper 95% confidence interval estimates 
(per the REMEDY database) to examine 
their effect on average annual per-patient 
costs (21).   
3. Results  
3.1 Baseline characteristics of the 
study sample costs  
The demographic characteristics of the 
study participants are provided in table 5. 
A majority of the participants were female 
(67%); with current age of the patients 
varying from to 24 to 81 years old. 
Participants were predominately from low-
income backgrounds, and most were 
unemployed. Forty-eight percent had 
valve surgery at some point in their 
lifetime, ranging 1980 to 2016. In 2016 the 
cardiac surgery theatre at GSH performed 
322 valve replacements, 56 of which were 
RHD related. The most common valve 
replacement types were aortic (46%), 
mitral (41%), and mixed aortic and mitral 
(13%).  
Table 5: Demographic characteristics of 100 
individuals with RHD participating in the 
REMEDY study 
Population 
description    
Study population 
outcome 
Mean age 47.5 years 
Gender 67 % Female 
33 % Male 
Marital status 52% Married 
40% Never married 
7% Widowed 
1% Divorced 
Employment 
history 
17% Employed  
1% Self-employed 
83% Unemployed 
Educational 
background 
2% No formal 
education 
3% Primary level  
81% Secondary level  
4% Tertiary level  
3.2 Costs of RHD Management 
from Provider Perspective 
3.2.1 Annual Per-Patient Cost of RHD 
Care 
The REMEDY database provided the 
number of visits and admissions for the 
100 patients that attended cardiac care at 
GSH. Utilisation data were collected over 
two consecutive years to capture longer-
term rates in clinically stable patients who 
only attend outpatient clinics (i.e., less 
frequently) (table 6). 
 
72 
  
Table 6: Average annual utilisation rates for 
RHD care at four clinical units at GSH 
Summaries of average annual per-patient 
costs for the four different clinical units 
(outpatient, ICU, cardiac cath lab, and 
surgical theatre) are provided in tables 7, 
8, 9 and 10, respectively. The cardiac 
medical and ICU care average unit 
outpatient accounted smallest portion of 
the average annual total costs for RHD 
care. Medications and staff costs were the 
driver of total costs of outpatient visits  
while blood transfusions and staff costs in 
inpatient medical and ICU care were the 
highest. Consumables costs were the 
drivers in the cardiac catheterisation 
laboratory and surgical theatre.  
The cost of routine medications was the 
major cost driver in outpatient clinic care 
(67%) followed by staff time (16% of cost). 
In the cath lab and surgical theater, 
consumables (such as prosthetic valves 
and specialised catheters) were the major 
driver (51% and 44%) respectively. Table 7- 
10 show detailed annual per-patient costs 
that comprise the weighted average cost. 
 As seen in table 11, RHD care costed GSH 
an estimated $2, 238, 294 (ZAR27 million) 
in 2017. The average cost per patient-year, 
based on utilisation data from the REMEDY 
study, was an estimated $4, 311 
(ZAR52 000). 
Table 7: Outpatient total and unit costs             
       
Cost component Annual total cost to 
GSH in 2017 (ZAR) 
             Unit cost per encounter 
in 2017 (ZAR) 
Step-down costing  
  
Personnel  R 2 300 000 R 670 
Overheads      R 250 000 R 72 
Maintenance          R 30 000 R 10 
Consumables         R 105 000 R 31 
Building         R 300 000 R 90 
Equipment & furniture        R 140 000 R 40 
Clinical 
unit 
Outp
atien
t 
clinic 
Medic
al and 
ICU 
Cath 
lab 
Surger
y/ 
theatr
e 
Per-
patient 
utlisatio
n rate 
per year 
2.9 0.31 0.19 0.22 
95% 
confiden
ce 
interval 
(2.0 - 
3.9 
(0.11 - 
0.50) 
(0.06
8 - 
0.31) 
(0.043- 
0.39) 
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Sub-total     R 3 200 000  R 920 
Ingredients costing  
  
Medications     R 1 950 000                             R 
2900  
Laboratory tests        R 320 000                              R 
470 
Sub-total    R 2 300 000 R 3 400 
Total cost                                                                                                                                                                                   R 5 500 000 R 4 300
Table 8: Cost of medical and ICU care  
 
Cost component Annual RHD care total cost 
to GSH in 2017 (ZAR) 
Unit cost per 
encounter in 2017 
(ZAR) 
Step-down costing 
  
Personnel  R 1 100 000 R 590 
Overheads     R 422 000 R 230 
Maintenance     R 50 000 R 26 
Consumables     R 320 000 R 170 
Building     R 490 000 R 260 
Equipment & furniture                                                                                                              R 40 000 R 85
Sub-total R 2 500 000 R 1 360 
Ingredients category 
 
Medications R 130 000 R 430 
Blood transfusions R 185 000 R 600 
Sub-total R 350 000 R 1050 
Total cost R  3 000 000 R 2 400 
Table 9: Cost of catheterization laboratory care 
 
Cost component Annual RHD care total cost 
to GSH in 2017 (ZAR) 
Unit cost per 
encounter in 2017 
(ZAR) 
Step-down costing 
  
Personnel  R 1 200 000 R 3 800 
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Maintenance R 41 000 R 130 
Consumables R 4 100 000    R 13 000 
Building R 407 000 R 1 300 
Equipment & furniture R 295 000 R 5 540 
Sub-Total  R 6 100 000 R 24 000 
Ingredients category 
 
Medications R 520 000 R 1 700 
Total cost                                                                        R 6 200 000  R 25 500 
Table 10: Surgery total and unit costs 
 
 
Cost component 
Annual RHD care total cost 
to GSH in 2017 (ZAR) 
Unit cost per 
encounter in 2017 
(ZAR) 
Step-down costing  
  
Personnel  R 2 800 000 R 31 000 
Maintenance  R 61 000 R 670 
General consumables  R 850 000 R 9 100 
Perfusion consumables R 3 400 000 R 37 000 
Anaesthesia Consumables R 240 000 R 2 700 
Prosthetic heart valves R 1 200 000 R 13 000 
Building R 610 000 R 6 700 
Equipment & furniture R 1 100 000 R 41 000 
Sub-total R 11 000 000 R 142 000 
 
Ingredients category 
  
Theatre medications             R 600 000 R 11 000 
Average annual per-patient 
theatre cost                            
R 12 000 000 R 153 000 
 
Table 7: Summary costs: Aggregate costs to GSH in 2017 and estimated annual costs per-
patient 
Clinical unit Aggregate cost 
to GSH in 2017 
(ZAR) 
% share of 
aggregate 
total cost 
Estimated per-
patient annual 
cost (ZAR) 
% share of 
per-patient 
annual cost 
Outpatient clinic R 5 500 000 21% R 12 500 24% 
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Cardiac medical 
ICU and ward 
R 3 000 000 11%     R 800 2% 
Cardiac 
catheterisation lab 
R 6 600 000 23% R 4 900 9% 
Surgical theatre R 12 000 000 45% R 34 000 65% 
Total R 27 000 000  R 52 000  
3.3 Sensitivity Analysis  
3.3.1 One-Way Univariate Sensitivity 
Analysis  
Figure 3 demonstrates the effects that 
varying utilisation rates at each of the four 
clinical units had on overall annual average 
per-patient costs. The costs were relatively 
less sensitive to variations in the discount 
rate (figure 4). In both sets of analyses, the 
influence of the parameters was largest on 
surgical theatre costs, since this was the 
most expensive clinical unit.  
 
 
Figure 3: Sensitivity analysis: variation in utilisation rates and their effect in annual cost of RHD 
per-patient 
 
 
 
 
 
-50% -30% -10% 10% 30% 50%
Outpatient visits
Medical and ICU care
Cath lab care
Theatre care
High utilisation rate (95% CI) Low utiliastion rate (95% CI)
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Figure 4: Sensitivity analysis: variations in discount rates and their effect on annual cost of RHD 
per patient 
 
4. Discussion  
This cost analysis sought to estimate, from 
the provider perspective, the annual cost 
of RHD care in a tertiary centre in the 
Western Cape Province of South Africa. 
RHD was estimated to cost GSH about $2, 
238, 294 (ZAR34 million) in the year 2017.  
Triangulating these estimates with data 
from the REMEDY registry, RHD was 
estimated to cost $4, 311 (ZAR52,000) per-
patient per year in total, with most of the 
total cost being driven by surgical theatre 
and cardiac catheterisation laboratory 
costs. This tertiary hospital based study 
indicates that average per-patient cost of 
RHD ZAR52, 000 ($4, 311) was much higher 
than the average annual per capita income 
of ZAR12, 860 ($1, 064) of a South African 
individual (44). On the other hand, RHD 
cost was also much higher than the cost of 
the facility-level care delivery of HIV/AIDS, 
drug sensitive tuberculosis, and 
hypertension, which have been estimated 
at 2016 $663 (ZAR8000) (41), 2015 $249 
(ZAR3000) (42) and 2016 $249 (ZAR3100) 
(43) per year, respectively. Although 
managing RHD costs more on a per-patient 
basis than all three of these conditions, it 
has been the most neglected (9).  
This study is the first of its kind in the 
African context. As summarised in a recent 
review, there have to date been no costing 
studies on RHD in Africa, and in fact, only 
-1.3% -0.8% -0.3% 0.2% 0.7% 1.2%
Outpatient visits
Medical and ICU care
Cath lab care
Theatre care
High utilisation rate (95% CI) Low utiliastion rate (95% CI)
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one prior costing study has been 
conducted in a developing country setting.  
Terreri et al., looking at RHD in Brazil, 
quantified per-patient direct costs of RHD 
and rheumatic fever from the provider 
perspective using the ingredients 
approach (1). Even after adjusting to a 
common currency and year, the cost 
estimates in this study are higher than in 
the Brazilian study, probably due to 
advances in care (i.e. new technologies) 
and to the fact that health sector prices 
tend to rise faster than inflation. In 
addition, the present study took a more 
detailed look at surgical care, the most 
expensive aspect of RHD care.  
This study assessed the cost of RHD to the 
public sector. It did not include ambulatory 
costs or admission costs from the private 
sector. It also did not look at patient costs, 
including so-called “direct non-medical 
costs” like transport and food, which – 
from a societal perspective – are a 
significant share of healthcare costs in 
South Africa (36, 40). However, the direct 
medical costs were still substantial, and 
from a societal perspective, the cost of 
surgical care from the provider perspective 
is probably the largest single driver of 
costs.  
It should be noted that the main cost 
contributors to outpatient RHD care were 
monthly medications cost followed by 
personnel cost. While major drivers for 
personnel costs were the major cost driver 
for inpatient medical and ICU ward care. 
These findings are similar to a study from 
Australia in which two-thirds of the cost of 
ICU care in tertiary hospitals was related to 
personnel (27). Rechner and Lipman (2005) 
predicted that consumables expenditure 
(in general) is likely to increase in the 
future in light of new innovations and 
therapies. Along these lines, the cardiac 
catheterisation laboratory and surgical 
theatre consumables were found to be 
major drivers of cost in this study. One 
implication of this study is that research on 
developing cheaper, locally made 
prosthetic valves and catheters should be 
supported, and measures should be taken 
to support the production and export of 
such products to other African countries 
(39).  
This study can also be viewed as an analysis 
of the economic consequences of 
inadequate prevention of rheumatic fever 
and RHD. RHD can be completely 
prevented by addressing bacterial sore 
throat in children using primary health 
centre-based approaches. When this 
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prevention window is missed, RHD 
develops and inevitably leads to heart 
valve damage, requiring one or more 
surgeries over the lifetime of most 
individuals. Several programmes in the 
Latin America region demonstrated 
reductions in healthcare costs from RHD of 
over 90% when comprehensive prevention 
efforts were undertaken (11). However, 
barriers such as shortage of skilled staff, 
poor public awareness about diagnosis and 
treatment of sore throat and poor access 
to primary care hindered wide adoption of 
primary prevention of the disease in South 
Africa (29) regardless of a plan to roll out 
comprehensive ASAP programme. This 
calls for policy implications for priority 
settings (such as Soweto) to improve 
community awareness and capture 
contemporary data on clinical course, 
complications and treatment practices 
between patients (14). One crucial aspect 
of ASAP is advocacy where disease 
notification is compulsory, yet the legal 
requirement to notify is neither been 
stressed nor implemented correctly 
resulting in poor capture of the disease 
burden (31). It is recommended for the 
department of health to establish a pilot 
web-based notification method in order to 
explore online notification submissions.  
Given the barriers, the present study cost 
estimates suggest that high cost burden of 
RHD will be reduced by reducing risk 
factors of AFR and increasing funds for 
ARF/RHD control measures. Mainly, the 
Western Cape Department of Health, and 
the NDoH to scale up RHD prevention 
efforts established on the best evidence-
based interventions in South Africa. 
 5. Limitations  
This study was a hospital-based cost 
analysis study with the usual limitations of 
such a study design. One hundred patient 
records were reviewed; however, some 
details were missing, while those with 
severe disease were often presented with 
little detail.  Nevertheless, considerable 
effort was taken to produce accurate and 
relevant estimates. There were a few other 
limitations to collecting information. First, 
the medication records did not 
disaggregate drugs related to RHD from 
drugs with other indications. Second, out 
of the 100-participant sample, only 88 
individuals were consistently engaged in 
RHD care in GSH. This finding raises the 
question of whether they were receiving 
care elsewhere and thus our costs were 
underestimates. Third, the step-down 
approach is not ideal for estimating some 
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costs such as diagnostics 
(echocardiography, etc) and pharmacy 
costs; better data would allow for more 
precise estimates of these costs using an 
ingredients approach. In addition, the cost 
of pharmacy services is likely to be higher 
at GSH than at health facilities in the 
community where most individuals with 
RHD receive the majority of their monthly 
prescriptions. Overall average annual per-
patient care costs are probably inflated 
compared to what they would be if 
referring hospitals and clinics had been 
sampled. 
6. Conclusion  
Despite its limitations, this study provides 
crucial contributions to the modest 
literature on the economics of RHD. It can 
serve as an input to future economic 
evaluations focused on RHD programmes 
and interventions in South Africa. It has 
also developed a costing framework and 
data collection tools that can be expanded 
to other aspects of RHD prevention and 
care as well as replicated in other African 
settings. The systematic and widespread 
collection of data on the cost of RHD will 
be a key component of raising awareness 
on the importance of the condition in 
Africa and of making the case for investing 
in RHD prevention. 
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Rheumatic heart disease (RHD) 
management and cost of tertiary level care 
in South Africa 
How much does it cost the Western Cape government to provide RHD care at a tertiary 
hospital? 
What is the economic burden of RHD on the public health system of South Africa? 
(By Assegid Hellebo) 
  
 
Key points 
✓ RHD is preventable, yet it 
continues to impose high financial 
and economic burden on the 
health systems of developing 
countries, and it is associated to 
more costly conditions (i.e. cardiac 
heart failure, stroke and 
premature death). 
✓ The estimated expenditure on RHD 
care at Groote Schuur Hospital in 
2017 was $2, 238, 294 (ZAR27 
million).  
✓ It costs about $4, 311 (ZAR52, 000) 
on average per-patient annually to 
deliver tertiary-level services to 
individuals with RHD. 
✓ Medication and consumable costs 
are the major drivers of outpatient 
and inpatient RHD care 
respectively.  
✓ Primary and secondary RHD 
prevention measures have not 
been fully implemented in South 
Africa. Closing these prevention 
gaps is an urgent priority if the high 
costs of tertiary level care are to be 
reduced. 
1. RHD and the Health System in South Africa 
The legacy of Apartheid has left South Africa with a health 
system that is inequitable, with the minority having 
disproportionate access to health services, leading to a 
situation where preventable diseases of poverty persist in 
low-income communities (Coovadia et al., 2009). Rheumatic 
heart disease (RHD) is a classic disease of poverty that is 
preventable by prompt delivery of preventive measures (sore 
throat treatment) in primary health centres. According to 
Drakensberg declaration of 2005, RHD is an important but 
neglected cause of cardiovascular disease in South Africa, 
especially among women and children (Mayosi et al., 2006) 
Globally, RHD accounts for 320,000 deaths annually (Naghavi 
et al., 2015). Recent evidence suggests a decline of RHD 
mortality in South Africa, though its incidence and prevalence 
have remained stable, placing a higher burden on the health 
system to provide chronic care (Zühlke et al., 2015; Mayosi, 
2016).  However, little is known about the cost of RHD care 
from the perspective of the South African government, which 
limits the public sector’s ability to allocate resources and 
assess new RHD technologies and interventions through 
comparative cost-effectiveness analyses (Irlam et al., 
2015).This policy brief summarises a cost analysis study that 
was conducted at Groote Schuur Hospital (GSH) in Cape Town 
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2. Study Methods and Findings 
This was a cost analysis from the provider perspective.  Patterns of RHD care at GSH were 
assessed for 100 patients participating in an RHD registry. A combination of step-down and 
ingredients costing approaches was used. The total cost of providing RHD care at GSH in 2017 
was about $2, 238, 294 (ZAR27 million). The cost of surgery accounted for 65% of total costs, 
and consumables such as cardiac catheters and prosthetic valves were the major drivers of 
cost. The breakdown of cost components is shown in figure 5. The estimated cost per-patient 
per year was $4, 311 (ZAR52, 000); again, most of this cost was due to surgical and cardiac 
catheterisation services.  
Figure 5: Distribution of cost components of RHD care at four clinical  
  
 
Personnel
16%
Overheads
2%
Maintenance 
0%
Building
2%
Consumables
1%
Equipment 
& 
Furniture
1%
Medications
67%
Laboratory tests
11%
OUTPATIENT CLINIC
Personn
el
24%
Overheads
10%
Maintenance 
1%
Building
11%Consumables 7%
Equipment & 
Furniture
4%
Medications
18%
Blood 
transfusi
ons
25%
MEDICAL & ICU
Personnel
15%
Maintenance 
1%
Consumab
les
51%
Building
5%
Equipment & 
Furniture
22%
Medications
7%
CATH LAB
Personnel
Maintenance
Consumables
Building
Equipment &
Furniture
Medications
Personnel
20%
Maintenance 
1%
General 
consumables
6%
Perfusion 
consumables
24%
Anaesthesia 
consumables
2%
Prostetic 
heart 
valves
9%
Building
4%
Equipmen
t & 
Furniture
27%
Medications
7%
CARDAIC SURGICAL 
THEATRE Personnel
Maintenance
General
consumables
Perfusion
consumables
Anaesthesia
consumables
Prostetic heart
valves
Building
Equipment &
Furniture
 
82 
  
3. Policy Implications 
In order to reduce the cost burden of RHD, the following policy interventions could be 
considered: 
➢ Comprehensive efforts could be undertaken to raise public and health professional 
awareness about the causes and consequences of RHD, stressing its preventable 
nature  
➢ The Department of Health could double down on investments in primary healthcare 
in order to achieve full population coverage of RHD prevention services. District and 
provincial level RHD registers could be supported in order to track patients early in 
the disease process and deliver preventive care that can delay or reduce the need 
for cardiac surgery.  
➢ Medications and consumables (including prosthetic heart valves) were major 
drivers of the cost of tertiary RHD care. The Department of Health could provide 
more support to academic and private sector research and development efforts 
that could eventually lead to cheaper alternatives. 
 
4. Conclusion 
RHD is a preventable cause of heart disease in South Africa that predominately affects 
children and working-age adults. Providing tertiary care is very expensive, at about $4, 311 
(ZAR52, 000) per-patient per year. Most of the current expenditure on RHD is avoidable, since 
highly effective preventive interventions exist. Conversely, failure to mitigate the disease in 
its earlier stages leads to higher costs to government. This study, the first of its kind in South 
Africa, can inform the allocation of resources for RHD prevention and care. 
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PART E: APPENDICES 
Appendix A: Data Collection Process Outline 
The data collection process will make use of data collection and management tool called 
Microsoft Excel (Microsoft Corporation, USA) in order to perform an organized gathering of 
information. Section A, B, C and D illustrates what data will be extracted from REMEDY study 
folders and/or database as well as the pricing of the quantities utilised by respective patients 
within the hospital.  
Section A: RHD Patient Identification/Information  
A1.      Selected patient code:  
 
 A2.       Age:   (years)     
 
 
A3.       Gender:           Male            
                                               
                                      Female 
                                                                          
                                                                                 Is this participant pregnant?   No 
 
                                                                                                                                       Yes  
 
A4. Disease severity       Mild                      Moderate                          Severe 
 
 
A5. Surgery performed     No 
       
                                              Yes 
                                                                                
                                                                                      How many times  
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Section B: Estimating Qualities of Resources Consumed by RHD Patients  
B1. Information on record - hospital visits 
B1.1                            Patient code  
B1.2 Date of first diagnosis ____/_____/________ 
B1.3 Date of first treatment  ____/_____/________ 
B1.4  How was the RHD patient 
diagnosed?  
a) Having symptoms (e.g. dry 
coughing) 
b) Routine screening in 
nearest clinic 
c) Routine screening in 
community/school 
d) Diagnosed for RHD while in 
clinic/hospital for other symptoms/disease 
Note down the existing medication routine of the patient for RHD care 
B1.4.1 Patient 
code 
B1.4.2 Medication name   B1.4.3 Dosage/quantity  B1.4.4 Rate/Frequency 
    
    
    
    
    
    
    
    
a) Quantity estimation for outpatient visits  
Unit/section Estimating quantity of resources/services  utilized 
Consultation time (CT) Time motion determined from non-participatory 
observation. Staff time spent per patient 
Admission time (AT) Time motion determined from non-participatory 
observation. Staff time per spent patient 
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Drugs and other medical supplies 
(consumables)  
Total quantity of the drugs, syringes, cotton amount 
utilized per-patient  
Laboratory tests  Total number of laboratory tests acquired per-patient  
 
b) Quantity estimation for inpatient visits  
Unit/section Estimating quantity resources/services utilized 
Inpatient visit days (IVDs) 
 
 
- IVDs hospitalization items  
Subtract a day a patient admitted (a) from a day 
discharged (b). Therefore, IVDs= ∑(b-a) 
Different indirect costs per inpatient days will be 
estimated using the actual resource (overheads) usage 
such as; building space and equipment’s. (overheads 
costing explained in section C below)  
Transport  Once we establish that specific patient was 
transported by ambulance as result of RHD or at least 
diagnosed for RHD after he/she arrived at the facility, 
we will obtain data from vehicle logbook. This will 
provide as the kilometres (KMs) travelled per patient, 
and we sum then up.  
Equipment  We will assume that equipment such as (bed, 
computers, cleaning machines) are assigned to the 
unit/section or each ward on the basis of inpatient 
days. The quantity allocation of resource utlisation will 
be obtained by dividing the amount of days/hours 
from inpatient visit to the lifetime of the respective 
equipment.  
Food  We assume that food is provided 3 times a day. 
However, we will engage with the respective hospital 
to confirm on the matter. To estimate the quantity of 
resource usage, we will multiply the number of food 
provided per day by the inpatient days.  
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Laundry service Laundry service utlisation will be apportioned to the 
unit/section on the basis of occupied bed days the 
same as the respective cost. 
Cleaning service Will be allocated on the basis proxy quota of floor 
space and the respective usage.  
 
Section C: Estimating Qualities of Overhead Resources Consumed by RHD Patients  
Overheads Quantity estimation 
Buildings ➢ Will be determined by means of annuity 
costs which refers to the current value of the 
buildings. 
➢ If the current value of the buildings is not 
on a record, we will estimate the costs based 
on the yearly building maintenance costs 
which we expect to acquire from the financial 
accounts GSH hospital 
➢ If the annuity costs for GSH hospital is 
available, we will utilize sum of annuity costs 
and yearly maintenance costs of this section 
of the hospital and divide by the number of 
RHD consultations per year which will be 
obtained from patient utilization of REMEDY 
study database. 
Vehicles ➢ Includes the cost of vehicles and cost of 
operating, maintaining and repairing, 
estimated through annuity function and 
yearly maintenance costs divided by amount 
of KMs driven per year. 
➢ Operation costs will be examined using 
obligation registers, or similar records using 
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hospital vehicle logbook, which often details 
the amount of kilometres travelled and the 
purpose of each journey 
Furniture ➢ Costs per test will be estimated based on 
replacement value (determined by annuity 
function) and yearly maintenance costs 
divided by the number of tests executed per 
year. 
➢ Replacement values can be obtained from 
hospital accounts, local suppliers, or 
manufacturers. 
➢ Finally we will allocate and estimate cost 
per activity by dividing the amount of 
days/hours the equipment lifetime be to the 
amount of days/hours utilized per patient. 
Medical Equipment ➢ This includes use of the laboratory and 
radiology facility including ultrasonography 
which will be measured through detailed re-
enactment of the patients procedures 
undergone. 
➢ If not available the laboratory overhead 
costs will be estimated using 5% of all the 
capital items in the laboratory. 
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Section D: Cost/Price Estimation Procedures for Direct and Indirect RHD Care 
Cost Component Methodology  Required data          Calculations 
Direct cost of RHD 
- Staff (Admin, 
consultation, HR) 
  
  
- D
rugs and test 
consumables 
 
 
 
  -   Equipment 
(furniture, medical 
equipment) 
Ingredient 
approach 
Productive working 
hours and minutes 
spent by the staff 
members per RHD 
patient 
Hours or minutes spent per-
patient with RHD multiplied by 
the respective price (average 
salary of the respective staff)  
 Ingredient 
approach 
The unit 
drug/consumables 
price per RHD patient 
The unit price per 
drug/consumables multiplied 
by utilisation per RHD patient 
Ingredient 
approach 
Purchasing value of 
each equipment, 
interest rate, life years, 
maintenance costs, 
total yearly utilisation 
of equipment for all 
RHD patients,  
utilisation per RHD 
patient 
Payment annuity (PMTa) = 
(equipment prices, life years, 
interest rates) plus 
maintenance costs/total yearly 
equipment utilization= 
(equipment cost per test) 
multiplied by utilisation per 
RHD patient 
Indirect cost of RHD 
-    Buildings, cars and 
overheads 
 Step-down 
approach 
Total inpatient 
day/days costs of 
hospital, total  number 
of inpatient days 
caused by RHD 
Total indirect costs of hospital 
divided by total number of 
inpatient days because of RHD 
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Appendix B: Observation Tool  
Section A: Estimating Waiting Times and Consultation Times     
Observation  date: ______/_____/_______ 
Facility:   
Observer’s name   
 
Unit/Section Time patient arrived to 
the office/unit/Section 
of staff or start time of 
the staff(a) 
Time the staff finalized 
treating/duty per-patient 
or end time of the staff 
(b) 
Total time spent 
(length of stay)  
(b-a) 
  
Admission       
medical officers       
Pharmacy       
Others units/sections 
                                          1.  
                                          2.  
      
      
      
 
Appendix C: Search Strategy 
Section A: Search Report: Studies of Cost of ARF and/or RHD Searches June 2017 
Search 
numbe
r 
Date 
searched 
Database search Hits (prior to 
unrelated and/or 
duplicate articles 
removal) 
Final hits results 
(after removing 
unrelated and/or 
duplicate articles) 
1 30/06/20
17 
PubMed (NCBI) 388 22 
2 30/06/20
17 
Scopus 64 3 
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3 04/07/20
17 
EBscoHost(CINAHAL) 12 2 
4 04/07/20
17 
EBscoHost (EconLit) 1 0 
5 04/07/20
17 
EBscoHost (Africa 
wide information) 
4 1 
6 03/07/20
17 
Central Cochrane 13 1 
 Total search=  481       Total references= 
29 
PubMed (NCBI) 
#43 Search ((((((((((((("Rheumatic Heart Disease"[Mesh]) OR "Rheumatic Fever"[Mesh]) OR 
rheumatic heart disease[Text Word]) OR acute rheumatic fever[Text Word]) OR rhd[Text 
Word]) OR infective endocarditis[Text Word]) OR bacterial endocarditis[Text Word]) OR 
neglected heart disease[Text Word]) OR rheumatic fever[Text Word]) OR rheumatic 
disorder[Text Word]) OR arf[Text Word])) AND ((((((((((("Costs and Cost Analysis"[Mesh])) OR 
cost[Text Word]) OR "Cost of Illness"[Mesh]) OR costs[Text Word]) OR "Economics"[Mesh]) 
OR economics[Text Word]) OR economic burden[Text Word]) OR total burden[Text Word]) 
OR economic evaluation[Text Word]) OR economic analysis[Text Word])) AND ((((((("Delivery 
of HealthCare"[Mesh]) OR "Health Care Sector"[Mesh]) OR ("Health Care Economics and 
Organizations"[Mesh])) OR health systems[Text Word]) OR health care system[Text Word]) 
OR health sector[Text Word]) OR health care provider[Text Word]) 
#42 Search ((((((((((((("Rheumatic Heart Disease"[Mesh]) OR "Rheumatic Fever"[Mesh]) OR 
rheumatic heart disease[Text Word]) OR acute rheumatic fever[Text Word]) OR rhd[Text 
Word]) OR infective endocarditis[Text Word]) OR bacterial endocarditis[Text Word]) OR 
neglected heart disease[Text Word]) OR rheumatic fever[Text Word]) OR rheumatic 
disorder[Text Word]) OR arf[Text Word])) AND ((((((((((("Costs and Cost Analysis"[Mesh])) OR 
cost[Text Word]) OR "Cost of Illness"[Mesh]) OR costs[Text Word]) OR "Economics"[Mesh]) 
OR economics[Text Word]) OR economic burden[Text Word]) OR total burden[Text Word]) 
OR economic evaluation[Text Word]) OR economic analysis[Text Word])) AND ((((((("Delivery 
of HealthCare"[Mesh]) OR "Health Care Sector"[Mesh]) OR ("Health Care Economics and 
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Organizations"[Mesh])) OR health systems[Text Word]) OR health care system[Text Word]) 
OR health sector[Text Word]) OR health care provider[Text Word]) Sort by: [pubsolr12] 
#41 Search (((((("Delivery of Health Care"[Mesh]) OR "Health Care Sector"[Mesh]) OR ("Health 
Care Economics and Organizations"[Mesh])) OR health systems[Text Word]) OR health care 
system[Text Word]) OR health sector[Text Word]) OR health care provider[Text Word] 
#40 Search (((((((((("Costs and Cost Analysis"[Mesh])) OR cost[Text Word]) OR "Cost of 
Illness"[Mesh]) OR costs[Text Word]) OR "Economics"[Mesh]) OR economics[Text Word]) OR 
economic burden[Text Word]) OR total burden[Text Word]) OR economic evaluation[Text 
Word]) OR economic analysis[Text Word] 
#39 Search health care provider[Text Word] 
#38 Search health sector[Text Word] 
#37 Search health care system[Text Word] 
#36 Search health systems[Text Word] 
#35 Search "Health Care Economics and Organizations"[Mesh] Sort by: [pubsolr12] 
#33 Search "Health Care Sector"[Mesh] Sort by: [pubsolr12] 
#31 Search "Delivery of Health Care"[Mesh] Sort by: [pubsolr12] #29 Search economic 
analysis[Text Word] 
#28 Search economic evaluation[Text Word] 
#26 Search total burden[Text Word] 
#25 Search economic burden[Text Word] 
#24 Search economics[Text Word] 
#23 Search "Economics"[Mesh] Sort by: [pubsolr12] 
#21 Search costs[Text Word] 
#20 Search "Cost of Illness"[Mesh] Sort by: [pubsolr12] 
#18 Search cost[Text Word] 
#17 Search "Costs and Cost Analysis"[Mesh] Sort by: [pubsolr12] 
#15 Search (((((((((("Rheumatic Heart Disease"[Mesh]) OR "Rheumatic Fever"[Mesh]) OR 
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